

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
16 December 2004 (16.12.2004)

PCT

(10) International Publication Number
WO 2004/108692 A1

(51) International Patent Classification⁷: C07D 241/20, 403/12, 417/12, 401/12, 413/12, A61K 31/4965, 31/497, A61P 11/06, 29/00

(74) Agent: ASTRAZENECA; Global Intellectual Property, S-151 85 Södertälje (SE).

(21) International Application Number:
PCT/SE2004/000850

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 2 June 2004 (02.06.2004)

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/108692 A1

(54) Title: SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4)

(57) Abstract: The invention relates to sulphonamide compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

NOVEL COMPOUNDS

- 5 The present invention relates to sulphonamide compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

10 Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small-secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. At the present time, the chemokine superfamily comprises three groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C), Cys-Cys (C-C) 15 and Cys-X₃-Cys (C-X₃-C) families. The C-X-C and C-C families have sequence similarity and are distinguished from one another on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues. The C-X₃-C family is distinguished from the other two families on the basis of having a triple amino acid insertion between the NH-proximal pair of cysteine residues.

20 The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).


25 The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils. Examples include human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins 1 α and 1 β (MIP-1 α and MIP-1 β), Thymus and Activation Regulated Chemokine (TARC, CCL17) and Macrophage Derived Chemokine (MDC, CCL22).

30 The C-X₃-C chemokine (also known as fractalkine) is a potent chemoattractant and activator of microglia in the central nervous system (CNS) as well as of monocytes, T cells, NK cells and mast cells.

35 Studies have demonstrated that the actions of chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C

family) and CX₃CR1 for the C-X₃-C family. These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.

- 5 The present invention therefore provides a compound of formula (I) and pharmaceutically acceptable salts, solvates or N-oxides thereof:



10 in which:

Ar^1 is phenyl or thienyl, each of which is optionally substituted by one to three substituents R^1 , R^2 and R^3 selected from halogen, cyano, CF_3 , OCF_3 , OC_{1-6} alkyl or C_{1-6} alkyl;

15 R^4 is C_{1-6} alkoxy where the alkyl group may form a 3-6 membered saturated ring or may be substituted with 1-3 fluorine atoms or a cyano group; or

OC_{1-6} alkyl R^{11} , or OC_{2-6} alkyl-X-R¹¹ where the alkyl group may form a 3-6 membered saturated ring and is optionally substituted with 1-3 groups selected from hydroxy, halogen, $\text{NR}^{14}\text{R}^{15}$, SR^{13} , $\text{S(O)}_2\text{R}^{13}$, $\text{S(O)}\text{R}^{13}$ or COR^{13} ;

20 one of R^5 or R^6 is $\text{XCH}_2\text{C}_{1-4}$ alkyl where the alkyl group is substituted at any position by the two groups R^{11} and either $\text{NR}^{14}\text{R}^{15}$ or hydroxy, or R^5/R^6 is XR^{16} where R^{16} is a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen or sulphur and optionally substituted with 1-3 groups selected from hydroxy, cyano, halogen and =O, and R^{16} is substituted by R^{11} ;

25 and the other is hydrogen, halogen, amino, NHC_{1-6} alkyl, $\text{N}(\text{C}_{1-6}$ alkyl)₂, C_{1-6} alkoxy or C_{1-6} alkyl optionally substituted by one or more fluoro or hydroxyl groups;

30 X is NR^{13} , O, S, S(O) , S(O)_2 , or a bond;

R^{11} is an aryl group or a 5-7 membered heteroaromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, which aryl group or heteroaromatic ring can be optionally substituted by 1-3 groups selected from halogen, $\text{C(O)}\text{NR}^{14}\text{R}^{15}$, $\text{C(O)}\text{OR}^{12}$,

hydroxy, =O, =S, CN, NO₂, COR¹³, NR¹⁴R¹⁵, X(CH₂)qNR¹⁴R¹⁵, (CH₂)nNR¹⁴R¹⁵, (CH₂)nOH, SR¹³, S(O)R¹³, S(O)₂R¹³

C₁₋₆ alkyl-X-C₁₋₆ alkyl, C₁₋₆ alkyl or C₁₋₆ alkoxy where the alkyl group may form a 3-6 membered ring or is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR¹⁴R¹⁵, SR¹³, S(O)R¹³, S(O)₂R¹³; or

R¹¹ is C(O)NR¹⁴R¹⁵, C(O)OR¹², CH₂OR¹²

R¹² and R¹³ are independently hydrogen or C₁₋₆ alkyl where the alkyl group may be substituted with 1-3 fluorine atoms or may form a saturated 3-6 membered ring;

R¹⁴ and R¹⁵ are independently hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, (CH₂)qOH or (CH₂)qNH₂,

or R¹⁴ and R¹⁵ together with the nitrogen atom to which they are attached form a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen and sulphur and optionally substituted by C₁₋₆ alkyl, C₁₋₆ alkyl-OH, or hydroxy; and

n is 1, 2, 3, 4 or 5; and

q is 2, 3, 4, 5 or 6,

- provided that where X is a bond then R⁵/R⁶ is not XCH₂C₁₋₄alkylR¹¹.

The term aryl includes phenyl and naphthyl. The term alkyl, whether alone or as part of another group, includes straight chain and branched chain alkyl groups. Examples of 5- to 7-membered heteroaromatic rings containing 1 to 4 heteroatoms include thienyl, furanyl, pyrrolyl, imidazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, triazinyl, oxazolyl, thiazolyl, isoxazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl.

Examples of saturated 4- to 8-membered rings containing 1 to 3 heteroatoms include morpholine, piperidine and azetidine. Substituents on any rings can be present in any suitable ring position including suitable substituents on nitrogen atoms.


Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect of the present invention.

Preferably Ar¹ is phenyl, more preferably substituted by one or more halogen atoms.


Preferred halogen groups for R¹, R² and R³ are chloro, bromo and fluoro. Preferably one of R¹, R² and R³ is hydrogen and the others are chloro, bromo or methyl. More preferably R¹ and R² are chloro at the 2- and 3-positions of the phenyl ring and R³ is hydrogen (i.e. 5 2,3-dichlorophenyl), R¹ and R³ are chloro at the 2- and 4-positions of the phenyl ring and R² is hydrogen (i.e. 2,4-dichlorophenyl) or R¹ is chloro at the 2-position and R² is methyl at the 3-position of the phenyl ring and R³ is hydrogen (i.e. 2-chloro-3-methylphenyl). Most preferably R¹ and R² are chloro at the 2- and 3-positions of the phenyl ring and R³ is 10 hydrogen (i.e. 2,3-dichlorophenyl).

Preferably R⁴ is methoxy.

For R⁵ examples of NR¹⁴R¹⁵ include morpholine, pyrrolidine, NMe₂, NH₂, NHMe, and the 15 groups below:



Examples of XCH₂C₁₋₄ alkyl where the alkyl group is substituted at any position by the two 20 groups R¹¹ and either NR¹⁴R¹⁵ or hydroxy include SCH₂CH(Ph)NH₂ and OCH₂CH(pyridyl)OH. Examples of XR¹⁶ where R¹⁶ is substituted by R¹¹ include the groups below:



Preferably R⁵ is XCH₂CH(R¹¹)NR¹⁴R¹⁵ where R¹¹ is CO₂Me or CONHMe or a 5 or 6-30 membered heterocycle and NR¹⁴R¹⁵ is NH₂ or NHMe and X is S or O. More preferably R⁵ is XCH₂CH(R¹¹)NR¹⁴R¹⁵ where R¹¹ is CO₂Me, 2-thiazole or C(O)NHMe, and NR¹⁴R¹⁵ is NH₂ and X is S.

Preferably R⁶ is hydrogen, chloro or methyl.

Preferably X is NR¹³, O, S, S(O) or S(O)₂.

Preferred compounds of the invention include:

- 5 S-[5-[[2,3-Dichlorophenyl]sulfonyl]amino]-6-methoxypyrazinyl]-D-cysteine, methyl ester
S-[5-[[2,3-Dichlorophenyl]sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine, methyl ester
S-[5-[[2,3-dichlorophenyl]sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine
(2R)-2-amino-3-[[5-[[2,3-dichlorophenyl]sulfonyl]amino]-6-
methoxypyrazinyl]thio]propanamide
10 (2R)-2-amino-3-[[5-[[2,3-dichlorophenyl]sulfonyl]amino]-6-
methoxypyrazinyl]thio]propanamide
(2R)-2-amino-3-[[5-[[2,3-dichlorophenyl]sulfonyl]amino]-6-methoxypyrazinyl]thio]-N,N-
dimethylpropanamide
N-[5-[(2R)-2-amino-3-hydroxypropyl]thio]-3-methoxypyrazinyl]-2,3-dichloro
15 benzenesulfonamide
S-[3-chloro-5-[[2,3-dichlorophenyl]sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine,
methyl ester
S-[3-chloro-5-[[2,3-dichlorophenyl]sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine
N-[5-[(2R)-2-amino-3-hydroxypropyl]thio]-6-chloro-3-methoxypyrazinyl]-2,3-
20 dichlorobenzenesulfonamide
S-[5-[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxy-3-methylpyrazinyl]-L-cysteine,
methyl ester
S-[5-[[2,3-dichlorophenyl]sulfonyl]amino]-6-methoxy-3-methylpyrazinyl]-L-cysteine,
N-(2-Aminoethyl)-S-[5-[[2,3-dichlorophenyl]sulfonyl]amino]-6-methoxypyrazinyl]-L-
25 cysteine, ethyl ester
N-[5-[(2R)-2-amino-2-phenylethoxy]-3-methoxypyrazinyl]-2,3-
dichlorobenzenesulfonamide
2,3-Dichloro-N-[5-[[2-hydroxy-2-(2-thiazolyl)ethyl]thio]-3-methoxypyrazinyl]-
benzenesulfonamide
30 2,3-Dichloro-N-[5-[[2-hydroxy-2-(1-methyl-1H-imidazol-2-yl)ethyl]thio]-3-
methoxypyrazinyl]-benzenesulfonamide, potassium salt
2,3-Dichloro-N-[5-[[2-hydroxy-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-
benzenesulfonamide
35 N-[5-[[2-amino-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-
dichlorobenzenesulfonamide
2,3-dichloro-N-[5-[(2,3-dihydroxypropyl)thio]-3-methoxypyrazinyl] benzenesulfonamide

2,3-dichloro-*N*-[5-[(2-hydroxy-2-phenylethyl)thio]-3-methoxypyrazinyl]benzenesulfonamide

2,3-dichloro-*N*-[5-[[2-hydroxy-2-(3-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]benzenesulfonamide

5 *N*-[5-[[2-amino-2-(3-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide

2,3-dichloro-*N*-[5-[[2-hydroxy-2-(4-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]benzenesulfonamide

10 *N*-[5-[[2-hydroxy-2-(2-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]benzenesulfonamide

3-[[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-(2*R*)-2-hydroxypropanoic acid, methyl ester

N-[5-[[2-amino-2-(2-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide

15 *N*-[5-[[2-amino-2-(1-methyl-1*H*-imidazol-2-yl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide

(2*R*)-2-amino-3-[[3-chloro-5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-*N*-methylpropanamide

(2*R*)-2-amino-3-[[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxy-3-methylpyrazinyl]thio]-*N*-methylpropanamide

20 *N*-[5-[[2-amino-2-(2-thiazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide

N-[5-[(2*R*)-2-Amino-3-hydroxypropyl]oxy]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide, monohydrochloride

25 2,3-Dichloro-*N*-[5-[[2*S*]-2,3-dihydroxypropyl]oxy]-3-methoxypyrazinyl]-benzenesulfonamide

2,3-Dichloro-*N*-[5-[(2*R*)-2,3-dihydroxypropyl]oxy]-3-methoxypyrazinyl]-benzenesulfonamide


30 *N*-[5-[(2*R*)-2-Amino-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide

N-[5-[[*(2R*)-2-Amino-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]thio]-3-methoxy-6-methylpyrazinyl]-2,3-dichlorobenzenesulfonamide

N-[5-[[*(2R*)-2-Amino-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]thio]-6-chloro-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide

5 and pharmaceutically acceptable salts and solvates thereof.

According to the invention there is also provided a process for the preparation of compound (I) which comprises reaction of a compound of formula (II):



where Ar^1 , R^4 and R^6 are as defined above, P is a suitable protecting group (e.g. trimethylsilylethoxymethyl (SEM)) and X is a leaving group (e.g. chloro or bromo) with a


15 compound $\text{R}^5\text{-H}$ in the presence of a base, and optionally thereafter,

- removing any protecting groups
- forming a pharmaceutically acceptable salt.

The reaction may conveniently be carried out in a solvent (e.g. acetonitrile) at room

20 temperature using a base (e.g. caesium carbonate). The protecting group P is typically removed using an acid such as trifluoroacetic acid in a solvent such as dichloromethane at room temperature.

Compounds of formula (II) may be prepared from compounds of formula (III)



(III)


where Ar^1 , R^4 , R^6 and X are as defined above by reaction with a suitable protecting reagent such as 2-(trimethylsilyl)ethoxymethyl chloride (SEM-Cl). The reaction may be performed in a solvent such as dichloromethane in the presence of a base such as diisopropylamine at room temperature.

5

Compounds of formula (III) where Ar^1 , R^4 and R^6 are as defined in formula (I) or are protected derivatives thereof and X is a leaving group such as chloro or bromo may be prepared either:-

10

(a) from compounds of formula (IV):




15

(IV)

where Ar^1 and R^6 are as defined above and X and L are leaving groups such as chloro or bromo by reaction with a compound $\text{R}^4\text{-H}$ in the presence of a suitable base. The compound $\text{R}^4\text{-H}$ may be used as the solvent, such as methanol, in which case a suitable base would be sodium methoxide, and the reaction may be performed at a temperature between 20°C and 100°C, or

(b) from compounds of formula (V) where R^4 and R^6 are as defined above and X is a leaving group such as chloro or bromo by reaction with a sulphonyl chloride of formula (VI) where Ar^1 is as defined in formula (I). The reaction may be carried out in a solvent such as dimethoxyethane, tetrahydrofuran or *N*-methylpyrrolidinone in the presence of a base such as sodium hydride or potassium *tert*-butoxide at room temperature.

20




(V)

(VI)

Compounds of formula (IV) may be prepared from compounds of formula (VII) where R⁶, X and L are as defined above by reaction with a sulphonyl chloride of formula (VI). The reaction may be carried out in a solvent such as dimethoxyethane, tetrahydrofuran or N-methylpyrrolidinone in the presence of a base such as sodium hydride or potassium *tert*-butoxide at room temperature.

10




(VII)

Compounds of formula (V) where R⁴ and R⁶ are as defined in formula (I) and X is a leaving group such as chloro or bromo may be prepared from compounds of formula (VII) where R⁶ and X are as defined above and L is a leaving group such as chloro or bromo by reaction with a compound R⁴-H in the presence of a suitable base. The compound R⁴-H may be used as the solvent, such as methanol, in which case a suitable base would be sodium methoxide, and the reaction may be performed at a temperature between 20°C and 100°C.

20


Compounds of formula (VII) where R⁶ is as defined in formula (I) and X and L are leaving groups such as bromo may be prepared from the reaction of compounds of the formula (VIII) where R⁶ is as defined above with a brominating agent such as bromine or N-bromosuccinimide. The reaction may be performed in a solvent such as chloroform at room temperature or reflux in the presence of a base such as pyridine.

25



(VIII)


Compounds of formula (VIII) are either commercially available or if R⁶ is methyl may be prepared from compounds of formula (IX) where L is a leaving group such as chloro by reaction with dimethylzinc in the presence of bis(diphenylphosphino)propane]nickel(II) chloride in a solvent such as dioxan at reflux.




Compounds of formula (VI) and (IX) are commercially available.

5

In addition, in the case where compound (I) has the formula




10 , wherein Ar¹, R⁴, R⁶ and R¹¹ are as defined above, there is provided a process for its preparation which comprises reacting a compound of formula (X),




15

wherein Ar¹, R⁴, R⁶ and R¹¹ are as defined above, with a suitable reducing agent such as triphenylphosphine in the presence of water. The reaction may conveniently be performed in a solvent, for example tetrahydrofuran, at room temperature.

20 Compounds of formula (X) where Ar¹, R⁴, R⁶ and R¹¹ are as defined above may be prepared from compounds of formula (XI) where Ar¹, R⁴, R⁶ and R¹¹ are as defined above and P is a suitable protecting group such as trimethylsilylethoxymethyl (SEM) by treatment with a suitable acid such as trifluoroacetic acid in a solvent such as dichloromethane. The reaction may be performed at room temperature.




Compounds of formula (XI) where Ar^1 , R^4 , R^6 , R^{11} and P are as defined above may be prepared from compounds of formula (XII) where Ar^1 , R^4 , R^6 , R^{11} and P are as defined above and X is a suitable leaving group such as chloro by treatment with a suitable metal azide such as sodium azide. The reaction may be performed in a solvent such as dimethylformamide at a temperature between 20°C and 100°C.



Compounds of formula (XII) where Ar^1 , R^4 , R^6 , R^{11} and P are as defined above and X is chloro may be prepared from compounds of formula (XII) where Ar^1 , R^4 , R^6 , R^{11} and P are as defined above and X is hydroxy by treatment with a suitable chlorinating agent such as methanesulphonyl chloride in the presence of a base such as triethylamine. The reaction may be carried out in a solvent such as dichloromethane at room temperature.

Compounds of formula (XII) where Ar^1 , R^4 , R^6 , R^{11} and P are as defined above and X is hydroxy may be prepared by either:-

- (a) treatment of compounds of formula (XIII):




where Ar¹, R⁴, R⁶ and P are as defined above with an aldehyde R¹¹CHO in the presence of a fluoride source such as tetrabutylammonium fluoride. The reaction may be performed in a solvent such as tetrahydrofuran at room temperature.

Compounds of formula (XIII) where Ar¹, R⁴, R⁶ and P are as defined above may be prepared from compounds of formula (II) where Ar¹, R⁴, R⁶ and P are as defined above by treatment with trimethylsilylmethanethiol in the presence of a base such as cesium carbonate. The reaction may be performed in a solvent such as acetonitrile at room temperature.

(b) treatment of compounds of formula (XIV):


15



where Ar¹, R⁴, R⁶ and P are as defined above with an epoxide of formula (XV) in the presence of a base such as potassium *tert*-butoxide. The reaction may be performed in a solvent such as tetrahydrofuran at room temperature.


Compounds of formula (XIV) where Ar¹, R⁴, R⁶ and P are as defined above may be prepared from compounds of formula (II) where Ar¹, R⁴, R⁶ and P are as defined above by treatment with 4-pyridineethanethiol in the presence of a base such as cesium carbonate. The reaction may be performed in a solvent such as acetonitrile at room temperature.

(c) treatment of compounds of formula (XVI):



where Ar¹, R⁴, R⁶ and P are as defined above with a reducing agent such as sodium borohydride. The reaction may be performed in a solvent such as ethanol at room temperature.

Compounds of formula (XVI) where Ar¹, R⁴, R⁶, R¹¹ and P are as defined above may be prepared from compounds of formula (XIV) where Ar¹, R⁴, R⁶ and P are as defined above by treatment with an alkylating agent of formula (XVII) where R¹¹ is as defined above and X is a leaving group such as chloro or bromo. The reaction may be performed in a solvent such as tetrahydrofuran at room temperature in the presence of a base such as potassium *tert*-butoxide.



It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as hydroxyl or amino groups in the starting reagents or intermediate compound may need to be protected by protecting groups. Thus, the preparation of the compound of formula (I) may involve, at an appropriate stage, the removal of one or more protecting groups. The protection and deprotection of functional groups is fully described in 'Protective Groups in Organic Chemistry', edited by J. W. F. McOmie, Plenum Press (1973), and 'Protective Groups in Organic Synthesis', 2nd edition, T. W. Greene & P. G. M. Wuts, Wiley-Interscience (1991).

The compounds of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably a basic addition salt such as sodium, potassium, calcium, aluminium, lithium, magnesium, zinc, benzathine, chloroprocaine, choline, diethanolamine, ethanolamine, ethyldiamine, meglumine, tromethamine or procaine, or an

acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or *p*-toluenesulphonate.

The compounds of formula (I) have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially CCR4) activity, and may be used in the treatment (therapeutic or prophylactic) of conditions/diseases in human and non-human animals which are exacerbated or caused by excessive or unregulated production of chemokines. Examples of such conditions/diseases include:

- (1) **(the respiratory tract)** obstructive airways diseases including chronic obstructive pulmonary disease (COPD); asthma, such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness); bronchitis; acute, allergic, atrophic rhinitis and chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous and pseudomembranous rhinitis and scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis; sarcoidosis, farmer's lung and related diseases, fibroid lung and idiopathic interstitial pneumonia;
- (2) **(bone and joints)** gout, rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis and Reiter's disease), Behcet's disease, Sjogren's syndrome and systemic sclerosis;
- (3) **(skin)** pruritis, scleroderma, otitus, psoriasis, atopical dermatitis, contact dermatitis and other eczematous dermatides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythemas, cutaneous eosinophilias, uveitis, Alopecia areata and vernal conjunctivitis, lupus;
- (4) **(gastrointestinal tract)** Coeliac disease, proctitis, eosinopilic gastro-enteritis, mastocytosis, inflammatory bowel diseases such as Crohn's disease, ulcerative colitis, ileitis and enteritis, food-related allergies which have effects remote from the gut, e.g., migraine, rhinitis and eczema;
- (5) **(central and peripheral nervous system)** Neurodegenerative diseases and dementia disorders, e.g. Alzheimer's disease, amyotrophic lateral sclerosis and other motor neuron diseases, Creutzfeldt-Jacob's disease and other prion diseases, HIV encephalopathy (AIDS dementia complex), Huntington's

disease, frontotemporal dementia, Lewy body dementia and vascular dementia; polyneuropathies, e.g. Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, plexopathies; CNS demyelination, e.g. multiple sclerosis, acute disseminated/haemorrhagic encephalomyelitis, and subacute sclerosing panencephalitis; neuromuscular disorders, e.g. myasthenia gravis and Lambert-Eaton syndrome; spinal disorders, e.g. tropical spastic paraparesis, and stiff-man syndrome; paraneoplastic syndromes, e.g. cerebellar degeneration and encephalomyelitis; CNS trauma; migraine; stroke and correctum diseases such as meningitis

10

- (6) **(other tissues and systemic disease)** hepatitis, vasculitis, spondyloarthropathies, vaginitis, glomerulonephritis, myositis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), lupus erythematosus, systemic lupus, erythematosus, Hashimoto's thyroiditis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, lepromatous leprosy, and idiopathic thrombocytopenia purpura; post-operative adhesions, and sepsis.
- (7) **(allograft and xenograft rejection)** acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin and cornea; and chronic graft versus host disease;
- (8) Cancer, carcinoma & tumour metastasis, including that of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid and skin, especially non-small cell lung cancer (NSCLC), malignant melanoma, prostate cancer and squamous sarcoma. Hematopoietic tumors of lymphoid lineage, including acute lymphocytic leukemia, B cell lymphoma and Burkitts lymphoma, Hodgkins Lymphoma, Acute Lymphoblastic Leukemia. Hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias and promyelocytic leukemia. Tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma, and other tumors, including melanoma, seminoma, tetratocarcinoma, neuroblastoma and glioma.
- (9) All diseases that result from a general imbalance of the immune system and resulting in increased atopic inflammatory reactions.
- (10) Cystic fibrosis, re-perfusion injury in the heart, brain, peripheral limbs and other organs.

15

20

25

30

35

(11) Burn wounds & chronic skin ulcers

5 (12) Reproductive Diseases (e.g. Disorders of ovulation, menstruation and implantation, Pre-term labour, Endometriosis)

10 (13) thrombosis

10 (14) infectious diseases such as HIV infection and other viral infections, bacterial infections.

Thus, the present invention provides a compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.

15 Preferably the compound of the invention are used to treat diseases in which the chemokine receptor belongs to the CC chemokine receptor subfamily, more preferably the target chemokine receptor is the CCR4 receptor.

20 Particular conditions which can be treated with the compound of the invention are asthma, rhinitis and inflammatory skin disorders, diseases in which there are raised TARC, MDC or CCR4 levels. It is preferred that the compound of the invention is used to treat asthma and rhinitis, especially asthma.

25 In a further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

30 In a still further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity, particularly CCR4 activity, is beneficial.

35 In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

The invention still further provides a method of treating a chemokine mediated disease wherein the chemokine binds to a chemokine (especially CCR4) receptor, which comprises

administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.

The invention also provides a method of treating a respiratory disease, such as asthma and

5 rhinitis, especially asthma, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.

10 For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.

15 The compound of formula (I) and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a

pharmaceutical composition in which the formula (I) compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

Depending on the mode of administration, the pharmaceutical composition will preferably

comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w,

20 still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50.%w, of active ingredient, all percentages by weight being based on total composition.

The present invention also provides a pharmaceutical composition comprising a compound

of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore

25 defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

The invention further provides a process for the preparation of a pharmaceutical

composition of the invention which comprises mixing a compound of formula (I), or a

pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, with a

30 pharmaceutically acceptable adjuvant, diluent or carrier.

The pharmaceutical compositions may be administered topically (e.g. to the lung and/or

airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols

and dry powder formulations; or systemically, e.g. by oral administration in the form of

35 tablets, capsules, syrups, powders or granules, or by parenteral administration in the form

of solutions or suspensions, or by subcutaneous administration or by rectal administration

in the form of suppositories or transdermally. Preferably the compound of the invention is

administered orally.

The invention further relates to combination therapies for the treatment of any one of rheumatoid arthritis, osteoarthritis, osteoporosis, psoriasis, inflammatory bowel diseases, COPD asthma, allergic rhinitis, atopic dermatitis or cancer or the neurodegenerative diseases such as multiple sclerosis, Alzheimer's disease or stroke.

5

For the treatment of rheumatoid arthritis, the compounds of the invention may be combined with "biological agents" such as TNF- α inhibitors such as anti-TNF monoclonal antibodies (such as Remicade, CDP-870 and Humira) and soluble TNF receptor immunoglobulin molecules (such as Enbrel.reg.). IL-1 receptor antagonist (such as Anakinra) and IL-1 trap, IL-18 receptor, anti-IL-6 Ab, anti-CD20 Ab, anti-IL-15 Ab and CTLA4Ig.

10

Suitable agents to be used in combination include standard non-steroidal anti-inflammatory agents (hereinafter NSAID's) such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, apazone, pyrazolones such as phenylbutazone, salicylates such as aspirin. The cyclooxygenase-2 (COX-2) inhibitors (such as meloxicam, celecoxib , rofecoxib, valdecoxib and etoricoxib) and the cyclo-oxygenase inhibiting nitric oxide donors (CINOD's) and the "disease modifying agents" (DMARDs) such as methotrexate, sulphasalazine, cyclosporine A, lefunomide; ciclesonide; hydroxychloroquine, d-penicillamine, auranofin or parenteral or oral gold.

15

The present invention still further relates to the combination of a compound of the invention together with a leukotriene biosynthesis inhibitor, 5-lipoxygenase (5-LO) inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist selected from the group consisting of zileuton; ABT-761; fenleuton; tepoxalin; Abbott-79175; Abbott-85761; N-(5-substituted)-thiophene-2-alkylsulfonamides; 2,6-di-tert-butylphenol hydrazones; methoxytetrahydropyrans such as Zeneca ZD-2138; the compound SB-210661; pyridinyl-substituted 2n cyanonaphthalene compounds such as L-739,010; 2-cyanoquinoline compounds such as L-746,530; indole and quinoline compounds such as MK-591, MK-886, and BAY x 1005.

20

The present invention still further relates to the combination of a compound of the invention together with a receptor antagonists for leukotrienes LTB₄, LTC₄, LTD₄, and LTE₄ selected from the group consisting of the phenothiazin-3-ones such as L-651,392; amidino compounds such as CGS-25019c; benzoxalamines such as ontazolast; benzenecarboximidamides such as BIIL 284/260; and compounds such as zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast

25

(CGP 45715A), and BAY x 7195.

The present invention still further relates to the combination of a compound of the invention together with a phosphodiesterase-4 (PDE4) inhibitor including inhibitors of the isoform PDE4D.

The present invention still further relates to the combination of a compound of the invention together with histaminic H₁ receptor antagonists including cetirizine, loratadine, desloratadine, fexofenadine, astemizole, azelastine, and chlorpheniramine.

10 The present invention still further relates to the combination of a compound of the invention together with a gastroprotective histaminic H₂ receptor antagonist or the proton pump inhibitors (such as omeprazole)

15 The present invention still further relates to the combination of a compound of the invention together with an α₁- and α₂-adrenoceptor agonist vasoconstrictor sympathomimetic agent, including propylhexedrine, phenylephrine, phenylpropanolamine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, and ethylnorepinephrine hydrochloride.

20 The present invention still further relates to the combination of a compound of the invention together with anticholinergic agents including ipratropium bromide; tiotropium bromide; oxitropium bromide; pirenzepine; and telenzepine.

25 The present invention still further relates to the combination of a compound of the invention together with a β₁- to β₄-adrenoceptor agonists including metaproterenol isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, and pirbuterol; or methylxanthanines including theophylline and aminophylline; sodium cromoglycate; or muscarinic receptor (M₁, M₂, and M₃) antagonist.

30 The present invention still further relates to the combination of a compound of the invention together with other modulators of chemokine receptor function such as CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX₃CR1 for the C-X₃-C family.

The present invention still further relates to the combination of a compound of the invention together with an insulin-like growth factor type I (IGF-1) mimetic.

The present invention still further relates to the combination of compound of the invention together with an inhaled glucocorticoid with reduced systemic side effects, including prednisone, prednisolone, flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, and mometasone furoate.

The present invention still further relates to the combination of a compound of the invention together with (a) tryptase inhibitors; (b) platelet activating factor (PAF) antagonists; (c) interleukin converting enzyme (ICE) inhibitors; (d) IMPDH inhibitors; (e) adhesion molecule inhibitors including VLA-4 antagonists; (f) cathepsins; (g) MAP kinase inhibitors; (h) glucose-6 phosphate dehydrogenase inhibitors; (i) kinin-B₁ - and B₂ - receptor antagonists; (j) anti-gout agents, e.g., colchicine; (k) xanthine oxidase inhibitors, e.g., allopurinol; (l) uricosuric agents, e.g., probenecid, sulfinpyrazone, and benzborumarone; (m) growth hormone secretagogues; (n) transforming growth factor (TGF β); (o) platelet-derived growth factor (PDGF); (p) fibroblast growth factor, e.g., basic fibroblast growth factor (bFGF); (q) granulocyte macrophage colony stimulating factor (GM-CSF); (r) capsaicin cream; (s) Tachykinin NK₁ and NK₃ receptor antagonists selected from the group consisting of NKP-608C; SB-233412 (talnetant); and D-4418; and (t) elastase inhibitors selected from the group consisting of UT-77 and ZD-0892 (u) induced nitric oxide synthase inhibitors (iNOS) or (v) chemoattractant receptor-homologous molecule expressed on TH2 cells, (CRTH2 antagonists).

The present invention still further relates to the combination of a compound of the invention together with an inhibitor of matrix metalloproteases (MMPs), i.e., the stromelysins, the collagenases, and the gelatinases, as well as aggrecanase; especially collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10), stromelysin-3 (MMP-11), and MMP12 inhibitors.

The compounds of the invention can also be used in combination with existing therapeutic agents for the treatment of osteoarthritis. Suitable agents to be used in combination include standard non-steroidal anti-inflammatory agents (hereinafter NSAID's) such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, apazone, pyrazolones such as phenylbutazone, salicylates such as aspirin, induced nitric oxide synthase inhibitors (iNOS inhibitors), COX-2 inhibitors such as celecoxib, valdecoxib, rofecoxib and etoricoxib, and the cyclo-oxygenase inhibiting nitric oxide donors (CINOD's) analgesics (such as paracetamol and tramadol), cartilage sparing agents

such as diacerein, doxycyline and glucosamine, and intra-articular therapies such as corticosteroids and hyaluronic acids such as hyalgan and synvisc and P2X7 antagonists.

The compounds of the invention can also be used in combination with existing therapeutic agents for the treatment of inflammatory bowel diseases (Ulcerative colitis and Crohn's disease). Suitable agents to be used include sulphasalazine, 5-amino-salicylates, the thiopurines, azathioprine and 6-mecaptourine and corticosteroids such as budesonide.

The compounds of the invention may also be used in combination with antiviral agents such as Viracept, AZT, aciclovir and famciclovir, and antisepsis compounds such as Valant.

The compounds of the present invention may also be used in combination with cardiovascular agents such as calcium channel blockers, lipid lowering agents such as statins, fibrates, beta-blockers, angiotensin converting enzyme (ACE) inhibitors, Angiotensin-2 receptor antagonists and platelet aggregation inhibitors.

The compounds of the present invention may also be used in combination with CNS agents such as antidepressants (such as sertraline), anti-Parkinsonian drugs (such as deprenyl, L-dopa, Requip, Mirapex, MAOB inhibitors such as selegiline and rasagiline, comP inhibitors such as Tasmar, A-2 inhibitors, dopamine reuptake inhibitors, NMDA antagonists, Nicotine agonists, Dopamine agonists and inhibitors of neuronal nitric oxide synthase), and anti Alzheimer's drugs such as donepezil, tacrine, COX-2 inhibitors, propentofylline or metryfonate.

The compounds of the present invention may also be used in combination with osteoporosis agents such as roloxiifene, droloxiifene, lasofoxifene or fosomax and immunosuppressant agents such as FK-506, rapamycin, cyclosporine, azathioprine, and methotrexate.

The compounds of the invention can also be used in combination with existing therapeutic agents for the treatment of cancer. Suitable agents to be used in combination include:

(i) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea, gemcitabine and paclitaxel (Taxol®); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-

C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and taxotere); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecin);

5 (ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and iodoxyfene), oestrogen receptor down regulators (for example fulvestrant), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase 10 inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5 α -reductase such as finasteride;

(iii) Agents which inhibit cancer cell invasion (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function);

15 (iv) inhibitors of growth factor function, for example such inhibitors include growth factor antibodies, growth factor receptor antibodies (for example the anti-erbB2 antibody trastuzumab [HerceptinTM] and the anti-erbB1 antibody cetuximab [C225]), farnesyl transferase inhibitors, tyrosine kinase inhibitors and serine/threonine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family 20 tyrosine kinase inhibitors such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, AZD1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI 1033)), for example inhibitors of the platelet-derived growth factor family and for example inhibitors 25 of the hepatocyte growth factor family;

(v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, (for example the anti-vascular endothelial cell growth factor antibody bevacizumab [AvastinTM], compounds such as those disclosed in International Patent Applications WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354) and 30 compounds that work by other mechanisms (for example linomide, inhibitors of integrin $\alpha\beta 3$ function and angiostatin);

(vi) vascular damaging agents such as Combretastatin A4 and compounds disclosed in International Patent Applications WO99/02166, WO00/40529, WO00/41669, WO01/92224, WO02/04434 and WO02/08213;

35 (vii) antisense therapies, for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense;

(viii) gene therapy approaches, including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or

a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and


(ix) immunotherapy approaches, including for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.

- 5 10 The following examples illustrate the invention. The title and sub-title compounds of the examples and methods were named using the Index naming programme verion 4.53/07 April 200 from Advanced Chemistry Development Inc.


Example 1

S-[5-[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl-D-cysteine, methyl ester

5



a) 2,3-Dichloro-N-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide




10 Sodium hydride (1.45g of 60%) was added to 3,5-dichloro-2-pyrazinamine (2.0g) in 1,2-dimethoxyethane (25mL) under nitrogen at room temperature. After 1 hour at room temperature, 2,3-dichlorobenzenesulphonyl chloride (2.94g) was added. After stirring for 30 minutes, 5% aqueous citric acid was added and the product extracted with ethyl acetate (x3). The combined extracts were washed with saturated brine, dried ($MgSO_4$) and the solvent was evaporated. Chromatography on silica eluting with dichloromethane/methanol mixtures gave the subtitled compound as a white solid (3.0g).

15 m/e 372 ($M-1^-$, 100%)

1H NMR (D6 DMSO) δ 8.29 (1H, s), 8.06 (1H, dd), 7.94 (1H, dd), 7.57 (1H, t)
MP 181-182°C

20

b) 2,3-Dichloro-N-(5-chloro-3-methoxypyrazinyl)benzenesulfonamide




A solution of 2,3-dichloro-*N*-(3,5-dichloro-2-pyrazinyl)benzenesulphonamide (20.0g) and sodium methoxide (7.0g) in methanol (300mL) was heated at reflux for 24 hours. The solvent was evaporated and the residue redissolved in water (500mL). The mixture was acidified to pH~1 with concentrated hydrochloric acid giving a white precipitate which was isolated by filtration and dried to afford the subtitled compound as a white solid (19.0g).

m/e 368 (M-1⁺, 100%)

¹H NMR (CDCl₃) δ 8.27 (1H, d), 7.84 (1H, br s), 7.70 (1H, d), 7.62 (1H, s), 7.41 (1H, t),

10 4.06 (3H, s).

c) 2,3-Dichloro-*N*-(5-chloro-3-methoxypyrazinyl)-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide




15 To a stirred solution of 2,3-dichloro-*N*-(5-chloro-3-methoxypyrazinyl)benzenesulfonamide (2.2g) and diisopropylethylamine (1.3mL) in dichloromethane (100mL) was added 2-(trimethylsilyl)ethoxymethyl chloride (1.3mL). After stirring for 30min at room temperature, the reaction mixture was washed with water and brine, and the organic phase dried over magnesium sulphate, filtered and evaporated to give a white solid. This was purified by silica gel chromatography, eluting with 10:1 isohexane:ethyl acetate, to afford the subtitled compound as a white solid (2.8g).

20 m/e 498 (M+1⁺, 100%)

¹H NMR (CDCl₃) δ 8.00 (1H, s), 7.97 (1H, dd), 7.67 (1H, dd), 7.29 (1H, t), 5.24 (2H, s), 3.91 (3H, s), 3.79-3.73 (2H, m), 0.87-0.82 (2H, m), 0.00 (9H, s).

d) *S*-[5-[[2,3-Dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]-D-cysteine, methyl ester




To a stirred solution of 2,3-Dichloro-N-(5-chloro-3-methoxypyrazinyl)-N-[2-(trimethylsilyl)ethoxy]methylbenzenesulfonamide (0.15g) and D-cysteine methyl ester hydrochloride (0.1g) in acetonitrile (5mL) was added caesium carbonate (0.39g) and the reaction mixture stirred at room temperature under an atmosphere of nitrogen for 18 hours.

After evaporation of solvent the residue was partitioned between brine and dichloromethane, and the organic phase dried over magnesium sulphate, filtered and evaporated. The crude product was purified by silica gel chromatography, eluting with 2:1 dichloromethane:ethyl acetate, to afford the subtitled compound as a colourless oil (0.09g). m/e 597 ($M+1^+$, 100%)

^1H NMR (CDCl_3) δ 7.97 (1H, d), 7.89 (1H, s), 7.65 (1H, d), 7.27 (1H, t), 5.23 (2H, s), 3.91 (3H, s), 3.81-3.68 (3H, m), 3.72 (3H, s), 3.26-3.19 (2H, m), 0.89-0.83 (2H, m), 0.00 (9H, s).

e) *S*-[5-[[2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-D-cysteine, methyl ester



A solution of *S*-[5-[[2,3-dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]-D-cysteine, methyl ester (0.08g) in a mixture of dichloromethane (5mL) and trifluoroacetic acid (3mL) was stirred at room temperature for 1 hour. After evaporation of solvent the residue was purified by

silica gel chromatography, eluting with 10:1 dichloromethane:methanol, to afford the title product as a white solid (0.05g).


m/e 465 (M-1⁻, 100%)

¹H NMR (CDCl₃) δ 8.05 (1H, d), 7.94 (1H, d), 7.69 (1H, s), 7.58 (1H, t), 4.36 (1H, t), 3.95 (3H, s), 3.71 (1H, dd), 3.60 (3H, s), 3.46 (1H, dd).

Example 2

¹⁰ S-[5-[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl-L-cysteine, methyl ester

a) S-[5-[(2,3-Dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl-N-[(1,1-dimethylethoxy)carbonyl]-L-cysteine, methyl ester




¹⁵ To a solution of 2,3-dichloro-N-(5-chloro-3-methoxypyrazinyl)-N-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide (0.300g) and N-[(1,1-

dimethylethoxy)carbonyl]-L-cysteine, methyl ester (0.13mL) in acetonitrile (10mL) was added caesium carbonate (0.200g) and the mixture stirred under nitrogen at room

²⁰ temperature for 24 hours. The mixture was added to water and the product extracted with ethyl acetate (x3). The combined extracts were washed with saturated brine, dried (MgSO₄) and the solvent was evaporated to give the subtitled compound as an oil (0.42g). m/e 697 (M-1⁻, 100%)

²⁵ b) S-[5-[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl-L-cysteine, methyl



ester

Procedure as for Example 1 step e) using S-[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl-N-[(1,1-dimethylethoxy)carbonyl]-L-cysteine, methyl ester (0.300g). Yield 0.075g.


5 m/e 467 ($M+1^+$, 100%)

^1H NMR (DMSO) δ 8.17 (2H, bs), 7.96 (1H, dd), 7.68 (1H, dd), 7.40 (1H, t), 7.34 (1H, s), 4.20 (1H, t), 3.83 (3H, s), 3.52 (3H, s), 3.40 (2H, m).

MP 170-4°C

10 Example 3

S-[5-[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl-L-cysteine



To a stirred solution of S-[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl-L-cysteine, methyl ester (0.100g) in tetrahydrofuran (20mL) was added a solution of lithium hydroxide (0.090g) in water (5mL). After stirring at room temperature for 4 hours, the reaction mixture was poured into 2M hydrochloric acid and extracted with dichloromethane (x3). The aqueous extract was evaporated to approximately 5mL. The title compound crystallised as a white solid (0.050g).

20 m/e 453 ($M+1^+$, 100%)


^1H NMR (DMSO) δ 8.51 (3H, bs), 8.05 (1H, d), 7.95 (1H, d), 7.71 (1H, s), 7.59 (1H, t), 4.21 (1H, m), 3.96 (3H, s), 3.75 (1H, dd), 3.51 (1H, dd).

MP 180-90°C

25 Example 4

(2R)-2-Amino-3-[[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]propanamide

a) S-[5-[(2,3-Dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]-N-[(1,1-dimethylethoxy)carbonyl]-L-cysteine




To a stirred solution of S-[5-[(2,3-dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]-N-[(1,1-dimethylethoxy)carbonyl]-L-cysteine, methyl ester (0.500g) in tetrahydrofuran (20mL) was added a solution of lithium hydroxide (0.300g) in water (5mL). After stirring at room temperature for 2 days, the reaction mixture was poured into saturated ammonium chloride solution and extracted with ethyl acetate (x2). The combined extracts were washed with saturated brine, dried (MgSO_4) and the solvent was evaporated. The residue was purified by silica gel chromatography, eluting with 3:1 ethyl acetate:methanol, to afford the subtitled product as a solid (0.200g).

m/e 681 ($M-1^-$, 100%)

b) [(1*R*)-2-Amino-1-[[5-[(2,3-dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]thio]methyl]-2-oxoethyl]carbamic acid, 1,1-dimethylethyl ester.

A solution of S-[5-[(2,3-dichlorophenyl)sulfonyl][[2-




(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]-N-[(1,1-dimethylethoxy)carbonyl]-L-cysteine (0.500g) in tetrahydrofuran (10mL) was cooled to 0°C under nitrogen and isobutyl chloroformate (0.105mL) was added dropwise. After 30

minutes at 0°C 0.88 ammonia solution was added and allowed to warm to room temperature. After stirring at room temperature for 24 hours, the reaction mixture was poured into saturated ammonium chloride solution and extracted with ethyl acetate (x3). The combined extracts were washed with saturated brine, dried (MgSO_4) and the solvent was evaporated to afford the subtitled product as an oil (0.550g).

5 m/e 682 ($M-1^+$, 100%).

c) (2*R*)-2-Amino-3-[[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]propanamide

10



Procedure as for Example 1 step e) using [(1*R*)-2-amino-1-[[[5-[(2,3-dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]thio]methyl]-2-oxoethyl]carbamic acid, 1,1-dimethylethyl ester (0.250g) Yield 0.150g.

15

m/e 452 ($M+1^+$, 100%)

^1H NMR (DMSO) δ 7.95 (1H, d), 7.77 (1H, s), 7.61 (1H, d), 7.48 (1H, s), 7.36 (2H, bs), 7.35 (1H, t), 7.33 (1H, s), 3.74 (1H, m), 3.28 (1H, m), 3.08 (1H, m).

MP 148-52°C


20

Example 5

(2*R*)-2-Amino-3-[[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-N-methyl-propanamide

25

a) [(1*R*)-1-[[[5-[(2,3-Dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-




6-methoxypyrazinyl]thio]methyl]-2-(methylamino)-2-oxoethyl]carbamic acid, 1,1-dimethylethyl ester.

Procedure as for Example 4 step b) using methylamine. Yield 0.230g.
m/e 696 ($M+1^+$, 100%)

5

b) (2*R*)-2-Amino-3-[[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-*N*-methylpropanamide,



Procedure as for Example 1 step e) using [(1*R*)-1-[[[5-[(2,3-dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]thio]methyl]-2-(methylamino)-2-oxoethyl]carbamic acid, 1,1-dimethylethyl ester (0.200g).

Yield 0.060g.

m/e 464 ($M-1^-$, 100%)


1H NMR (DMSO) δ 8.30 (1H, m), 8.05 (2H, bs), 7.96 (1H, dd), 7.63 (1H, dd), 7.36 (1H, t), 7.31 (1H, s), 3.80 (4H, m), 3.32 (3H, s), 3.25 (1H, m), 3.14 (1H, m).

MP 160-4°C

Example 6

(2*R*)-2-Amino-3-[[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-*N,N*-dimethylpropanamide

a) [(1*R*)-1-[[[5-[(2,3-Dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]thio]methyl]-2-(dimethylamino)-2-oxoethyl]carbamic acid 1,1-




dimethylethyl ester.

Procedure as for Example 4 step b) using dimethylamine. Yield 0.220g.

m/e 710 (M-1⁻, 100%)

- 5 b) (2*R*)-2-Amino-3-[[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-
N,N-dimethylpropanamide



Procedure as for Example 1 step e) using [(1*R*)-1-[[[5-[(2,3-dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]thio]methyl]-2-

- 10 (dimethylamino)-2-oxoethyl]carbamic acid, 1,1-dimethylethyl ester (0.200g).

Yield 0.055g.

m/e 480 (M+1⁺, 100%)


¹H NMR (DMSO) δ 8.05 (2h, bs), 7.95 (1H, d), 7.62 (1H, d), 7.35 (1H, t), 7.28 (1H, s),
 4.43 (1H, t), 3.81 (3H, s), 3.26 (1H, m), 3.15 (1H, m), 2.89 (3H,s), 2.66 (3H, s).

- 15 MP 187-90°C

Example 7

- 20 *N*-[5-[(2*R*)-2-Amino-3-hydroxypropyl]thio]-3-methoxypyrazinyl]-2,3-dichloro
 benzenesulfonamide


- a) [(1*R*)-2-[[5-[(2,3-Dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]thio]-1-(hydroxymethyl)ethyl]carbamic acid, 1,1-dimethylethyl ester



To a stirred solution of S-[5-[[2,3-dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]-N-[(1,1-dimethylethoxy)carbonyl]-L-cysteine, methyl ester (0.120g) in tetrahydrofuran (10mL)

- 5 under nitrogen was added a 1.0M solution of lithium triethylborohydride in tetrahydrofuran (0.7mL). After stirring at room temperature for 1 day, the reaction mixture was poured into saturated ammonium chloride solution and extracted with ethyl acetate (x3). The combined extracts were washed with saturated brine, dried (MgSO_4) and the solvent evaporated. The residue was purified by silica gel chromatography, eluting with 2:3 ethyl
10 acetate:isohexane, to afford the subtitled product as an oil (0.075g).
m/e 669 ($\text{M}+1^+$, 100%)

b) N-[5-[(2*R*)-2-Amino-3-hydroxypropyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide



- 15 Procedure as for Example 1 step e) using [(1*R*)-2-[[5-[[2,3-dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]thio]-1-(hydroxymethyl)ethyl]carbamic acid, 1,1-dimethylethyl ester (0.075g).
Yield 0.024g.
m/e 437 ($\text{M}-1^+$, 100%)


¹H NMR (DMSO) δ 8.05-7.93 (4H, m), 7.71 (1H, s), 7.58 (1H, t), 5.38 (1H, m), 3.94 (3H, s), 3.66-3.23 (5H, m).

Example 8

5

S-[3-Chloro-5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl-L-cysteine, methyl ester

a) 3-Methoxy-5-bromo-6-chloro-2-pyrazinamine




10

A stirred solution of 2-amino-6-chloropyrazine (2.0g) and *N*-bromosuccinimide (13.71g) in chloroform (100 mL) was heated to reflux for 20 hours. The reaction mixture was cooled and concentrated onto silica gel (20g) and the residue loaded onto a column of silica gel (5cm x 2cm) and the column was eluted with dichloromethane. Concentration afforded 3,5-dibromo-6-chloro-2-aminopyrazine that was dissolved into methanol (200 mL) and sodium methoxide (32g of a 25% solution in methanol) added. The reaction was heated to 70°C for 1.5h, cooled and concentrated to approx. 50 mL capacity. The reaction mixture was poured into water (200mL) and the sub-titled adduct (2.0g) collected as an off-white solid.

15

m/e 235, 237 (M+1⁺, 100%)

b) *N*-(5-Bromo-6-chloro-3-methoxypyrazinyl)-2,3-dichlorobenzenesulphonamide




Procedure as for Example 1 step a), (reaction performed at room temperature) using 3-

methoxy-5-bromo-6-chloro-2-pyrazinamine (Example 125a) (0.5g) and 2,3-dichlorobenzenesulphonyl chloride (2.21g). Yield 3.2g.

m/e 445, 447 (M-1⁺, 100%)

¹H NMR (CDCl₃) δ 8.32 (1H, dd), 7.79 (1H, br), 7.72 (1H, dd), 7.45 (1H, t), 4.05 (3H, s). MP 177-178°C

c) *N*-(5-bromo-6-chloro-3-methoxypyrazinyl)-2,3-dichloro-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide




Procedure as for Example 1 step c) using *N*-(5-Bromo-6-chloro-3-methoxypyrazinyl)-2,3-dichlorobenzenesulphonamide (1.75g). Yield 2.20g.

5 m/e 447 ($M+1$ -SEM $^+$, 100%)

1 H NMR ($CDCl_3$) δ 8.02 (1H, d), 7.71 (1H, d), 7.35 (1H, t), 5.23 (2H, s), 3.96 (3H, s), 3.72 (2H, t), 0.84 (2H, t), 0.00 (9H, s).

d) *S*-[3-Chloro-5-[[2,3-dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-

10 6-methoxypyrazinyl-*N*-[(1,1-dimethylethoxy)carbonyl]-L-cysteine, methyl ester




Procedure as for Example 2 step a) using *N*-(5-bromo-6-chloro-3-methoxypyrazinyl)-2,3-dichloro-*N*-[(2-(trimethylsilyl)ethoxy)methyl]benzenesulfonamide (0.400g). Yield 0.480g.

m/e 631 ([M-Boc] $+1$ $^+$, 100%)

15

e) *S*-[3-Chloro-5-[[2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl-L-cysteine,



methyl ester

Procedure as for Example 1 step e) using *S*-[3-chloro-5-[(2,3-dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]-*N*-[(1,1-

5 dimethylethoxy)carbonyl]-L-cysteine, methyl ester (0.300g). Yield 0.120g.
m/e 503 ($M+1^+$, 100%)

^1H NMR (DMSO) δ 8.40 (2H, bs), 8.02 (1H, d), 7.65 (1H, d), 7.39 (1H, t), 4.30 (1H, m), 3.86 (3H, s), 3.66 (1H, m), 3.61 (3H, s), 3.34 (1H, m).


MP 170-3°C

10

Example 9

S-[3-Chloro-5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine

15 Procedure as for Example 3 using *S*-[3-chloro-5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-



methoxypyrazinyl]-L-cysteine, methyl ester (0.070g). Yield 0.050g

m/e 488 ($M+1^+$, 100%)


^1H NMR (DMSO) δ 8.51 (3H, bs), 8.03 (1H, dd), 7.70 (1H, d), 7.42 (1H, t), 4.16 (1H, m), 3.87 (3H, s), 3.74 (1H, dd), 3.30 (1H, m).

20 MP 170-3°C

Example 10

N-[5-[(2*R*)-2-Amino-3-hydroxypropyl]thio]-6-chloro-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide

a) [(1*R*)-2-[[3-Chloro-5-[(2,3-dichlorophenyl)sulfonyl][[2-




(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]thio]-1-(hydroxymethyl)ethyl]carbamic acid, 1,1-dimethylethyl ester

Procedure as for Example 7 step a) using *S*-[3-chloro-5-[(2,3-dichlorophenyl)sulfonyl][[2-

5 (trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]-*N*-(1,1-dimethylethoxy)carbonyl]-L-cysteine, methyl ester (0.175g). Yield 0.170g
m/e 603 (M+1-BOC⁺, 100%)

b) *N*-[5-[(2*R*)-2-Amino-3-hydroxypropyl]thio]-6-chloro-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide



10

Procedure as for Example 1 step e) using [(1*R*)-2-[[3-chloro-5-[(2,3-dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]thio]-1-(hydroxymethyl)ethyl]carbamic acid, 1,1-dimethylethyl ester (0.170g).

15

Yield 0.032g.

m/e 475 (M+1⁺, 100%)

¹H NMR (DMSO) δ 8.01 (1H, dd), 7.91 (3H, bs), 7.63 (1H, t), 5.32 (1H, m), 3.82 (3H, s), 3.65 (1H, m), 3.57 (1H, m), 3.25-3.12 (2H, m).

MP 255-6°C


20

Example 11

S-[5-[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxy-3-methylpyrazinyl]-L-cysteine, methyl ester


25

a) 6-Methyl-2-pyrazinamine




Dimethylzinc (100mL of a 2M solution in toluene) was added dropwise over 0.5h to a stirred solution of 6-chloro-2-pyrazinamine (12.9g) and [1,3-
5 bis(diphenylphosphino)propane]nickel(II) chloride (5.4g) in dioxane (200mL) under a nitrogen atmosphere. The reaction mixture was heated at reflux for 18h, then cooled to room temperature and quenched cautiously with *iso*-propanol (30mL) and methanol (50mL). After removal of solvent *in vacuo*, the residue was partitioned between dichloromethane and aqueous ammonium chloride. The organic phase was filtered through celite, dried ($MgSO_4$), filtered and evaporated to give the crude product as an orange solid.
10 Chromatography on silica gel eluting with ethyl acetate/methanol mixtures gave the subtitle compound (5.1g). Used directly.

b) 3,5-Dibromo-6-methyl-2-pyrazinamine



15 A solution of bromine (1.85g) in chloroform (5mL) was added dropwise to a stirred solution of 2-amino-6-methylpyrazine (0.6g) and pyridine (0.9 ml) in chloroform (50mL). The reaction mixture was stirred at room temperature for 0.5h, then washed twice with water, dried ($MgSO_4$), filtered and evaporated to give the crude product as an orange solid.
20 Chromatography on silica gel eluting with dichloromethane gave the title compound (0.95g). Used directly.

c) 5-Bromo-3-methoxy-6-methyl-2-pyrazinamine




25 3,5-Dibromo-6-methyl-2-pyrazinamine (0.9g) was added to a solution of sodium (0.39g) in methanol (30mL) and the mixture heated at reflux for 18h. After removal of solvent *in vacuo*, the residue was partitioned between water and dichloromethane, and the organic phase dried ($MgSO_4$), filtered and evaporated to give the title compound as a pale yellow solid (0.58g).

m/e 218/220 ($M+1^+$, 100%)

¹H NMR ($CDCl_3$) δ 4.70 (2H, br s), 3.97 (3H, s), 2.40 (3H, s)

d) *N*-[5-Bromo-3-methoxy-6-methylpyrazinyl)-2,3-dichlorobenzenesulphonamide




Sodium hydride (0.5g of a 60% dispersion in oil) was added to a solution of 5-bromo-3-methoxy-6-methyl-2-pyrazinamine (0.55g) in *N*-methylpyrrolidinone (25mL). The resultant dark solution was stirred at room temperature for 0.5h before a solution of 2,3-dichlorobenzenesulphonyl chloride (0.67g) in *N*-methylpyrrolidinone (5mL) was added dropwise. The reaction mixture was stirred at room temperature for 3h, then quenched with aqueous ammonium chloride and partitioned between ethyl acetate and aqueous ammonium chloride (x5). The organic phase was dried (MgSO_4), filtered and evaporated to give the crude product. Chromatography on silica gel eluting with dichloromethane/ acetic acid (200:1) gave the sub-title compound as a pale yellow solid (0.38g).

m/e 424/426/428 (M-1⁻, 100%)

¹H NMR (CDCl_3) δ 8.29 (1H, d), 7.69 (2H, d), 7.41 (1H, t), 4.01 (3H, s), 2.27 (3H, s)
MP 146-148°C

15

e) *N*-(5-Bromo-3-methoxy-6-methylpyrazinyl)-2,3-dichloro-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide




Procedure as for Example 1 step c) using *N*-[5-bromo-3-methoxy-6-methylpyrazinyl)-2,3-dichlorobenzenesulphonamide (7.0g).

Yield 6.7g


¹H NMR (CDCl_3) δ 8.01 (1H, d), 7.68 (1H, d), 7.30 (1H, t), 5.24 (2H, s), 3.89 (3H, s), 3.74 (2H, m), 2.47 (3H, s), 0.84 (2H, m), 0.00 (9H, s).

f) *S*-[5-[[2,3-Dichlorophenyl]sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxy-3-methylpyrazinyl]-*N*-[(1,1-dimethylethoxy)carbonyl]-L-cysteine, methyl ester



- 5 Procedure as for Example 2 step a) using the product of Example 13 step e) (0.1g) and N-[(1,1-dimethylethoxy)carbonyl]-L-cysteine, methyl ester (0.05g).
Yield 0.045g.
- 10 ^1H NMR (CDCl_3) δ 8.01 (1H, d), 7.66 (1H, d), 7.28 (1H, t), 5.40 (1H, m), 5.21 (2H, AB), 4.65 (1H, m) 3.91 (3H, s), 3.77 (2H, m), 3.70 (3H, s), 3.52 (1H, m), 2.29 (3H, s), 1.43 (9H, s), 0.85 (2H, m), 0.01 (9H, s).


g) *S*-[5-[[2,3-Dichlorophenyl]sulfonyl]amino]-6-methoxy-3-methylpyrazinyl]-L-cysteine, methyl ester



- 15 Procedure as for Example 1 step e) using *S*-[5-[[2,3-dichlorophenyl]sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxy-3-methylpyrazinyl]-*N*-[(1,1-dimethylethoxy)carbonyl]-L-cysteine, methyl ester (0.045g).
Yield 0.018g.
m/e 481 ($\text{M}+1^+$, 100%)
- 20 ^1H NMR ($\text{D}_6\text{-DMSO}$) δ 8.07 (1H, d), 7.70 (1H, d), 7.43 (1H, t), 4.06 (1H, t), 3.81 (3H, s), 3.51 (3H, s), 3.53-3.49 (1H, m), 3.34-3.29 (1H, m), 1.92 (3H, s).
MP 164-168°C

Example 12

S-[5-[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxy-3-methylpyrazinyl-L-cysteine,
5 oxalate salt



A solution of *S*-[5-[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxy-3-methylpyrazinyl-L-cysteine, methyl ester (0.065g) and lithium hydroxide (0.011g) in tetrahydrofuran (2mL) and water (2mL) was heated at reflux for 4h. After removal of solvent *in vacuo*, the crude product was purified by reverse phase preparative hplc, followed by treatment with one equivalent of oxalic acid, to give the title compound as a pale brown solid.

Yield 0.021g.


m/e 467 ($M+1^+$, 100%)

^1H NMR (D6-DMSO) δ 8.07 (1H, d), 7.66 (1H, d), 7.41 (1H, t), 3.82 (3H, s), 3.73 (1H, dd), 3.51 (1H, d), 3.02 (1H, m), 1.92 (3H, s).

Example 13

N-(2-Aminoethyl)-*S*-[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl-L-cysteine, ethyl ester
20

a) *S*-[5-[(2,3-Dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl-L-cysteine, ethyl ester




Procedure as for Example 1 step d) using 2,3-dichloro-*N*-(5-chloro-3-methoxypyrazinyl)-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide (1.0g) and L-cysteine ethyl ester hydrochloride (0.45g).

5 Yield 0.9g.

¹H NMR (CDCl₃) δ 7.97 (1H, d), 7.89 (1H, s), 7.65 (1H, d), 7.27 (1H, t), 5.23 (2H, s), 4.18 (2H, q), 3.91 (3H, s), 3.80-3.71 (4H, m), 3.21-3.16 (1H, m), 1.26 (3H, t), 0.86 (2H, m), 0.01 (9H, s).

10 b) *N*-(2-Aminoethyl)-*S*-[5-[[2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine, ethyl ester



A solution of *S*-[5-[[2,3-dichlorophenyl)sulfonyl]][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]-L-cysteine, ethyl ester (0.35g),

15 *tert*-butyl *N*-(2-oxoethyl)carbamate (0.27g) and sodium triacetoxyborohydride (0.36g) in acetonitrile (7mL) was stirred at room temperature for 30min before removal of solvent *in vacuo*. The residue was dissolved in a mixture of dichloromethane (5mL) and trifluoroacetic acid (2mL) and stirred at room temperature for 1h. After removal of solvent *in vacuo*, the crude product was purified by silica gel chromatography, eluting with 10:1 dichloromethane:methanol, to afford the title product as a pale brown solid.

Yield 0.27g

m/e 522 (M-1⁺, 100%)

¹H NMR (CDCl₃) δ 8.21 (1H, d), 7.67 (1H, d), 7.56 (1H, br s), 7.40 (1H, t), 4.12 (2H, q), 4.03 (3H, s), 3.85 (1H, m), 3.69 (1H, m), 3.35 (1H, m), 3.25 (4H, br s), 1.20 (3H, t).


5

Example 14

N-[5-[(2R)-2-Amino-2-phenylethyl]oxy]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide

10

a) *N*-[5-[(2R)-2-Amino-2-phenylethyl]oxy]-3-methoxypyrazinyl]-2,3-dichloro-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide



15

2,3-Dichloro-*N*-(5-chloro-3-methoxypyrazinyl)-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide (0.25g) and R-(-)-2-phenylglycinol (0.075g) were dissolved in dry DMF (10 ml) under an atmosphere of nitrogen and treated with sodium hydride (60% suspension in oil, 0.035g). After stirring at ambient temperature for 20 hr the reaction was poured into brine and extracted with ethyl acetate (3 x 50 ml). The organic extracts were washed with brine, dried (MgSO₄) and evaporated to give the sub-title product as an oil.

20


Yield 0.2g.

m/e 599 (M⁺, 100%)

b) *N*-[5-[(2R)-2-Amino-2-phenylethyl]oxy]-3-methoxypyrazinyl]-2,3-

25

dichlorobenzenesulfonamide



The product from Example 14 step a) (0.2 g) was subjected to the procedure described for Example 1 step e) to afford the title product which crystallised from diethyl ether/hexane. Yield 0.032g


5 MP 138-140 °C

m/e 467 (M-1⁻, 100%)

¹H NMR (DMSO-d6) δ 7.92 (1H, dd), 7.64 (1H, dd), 7.32-7.53 (6H, m), 7.08 (1H, s), 4.63 (1H, m), 4.25-4.40 (2H, m), 3.76 (3H, s).


10 **Example 15**

2,3-Dichloro-N-[5-[[2-hydroxy-2-(2-thiazolyl)ethyl]thio]-3-methoxypyrazinyl]-benzenesulfonamide



15

a) 2,3-Dichloro-N-[3-methoxy-5-[[2-(4-pyridinyl)ethyl]thio]pyrazinyl]-N-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide




2,3-Dichloro-N-(5-chloro-3-methoxypyrazinyl)-N-[2-(trimethylsilyl)ethoxy]methylbenzenesulfonamide (10 g) and 4-pyridineethanethiol hydrochloride (4 g) were dissolved in acetonitrile (200 ml), treated with caesium carbonate (16 g) and stirred at ambient temperature for 24 hr. The mixture was partitioned between ethyl acetate (200 ml) and 2M HCl (200 ml). The ethyl acetate extract was washed with 2 M HCl (100 ml), water (100 ml), brine (100 ml), dried ($MgSO_4$) and evaporated to give the sub-title compound as a solid (9.1 g).

10

1H NMR ($CDCl_3$) δ 8.55 (2H, d), 7.99 (1H, m), 7.87 (1H, s), 7.67 (1H, m), 7.28 (1H, m), 7.15 (2H, d), 5.23 (2H, s), 3.90 (3H, s), 3.79 (2H, t), 3.40 (2H, t), 3.03 (2H, t), 0.87 (2H, t), 0.00 (9H, s).

15

b) 2-[[5-[(2,3-Dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]thio]-N-methoxy-N-methyl-acetamide.



The product from Example 15 step a) (4 g) was dissolved in dry THF (25 ml) under an atmosphere of nitrogen and treated with a 1 M solution of potassium *tert*-butoxide in THF


20

(10 ml), added dropwise. After stirring for 30 min the reaction was treated with a saturated solution of ammonium chloride (20 ml) followed by 2M HCl (100 ml) and extracted into ethyl acetate (200 ml). The ethyl acetate extract was washed with water (2 x 100 ml),

brine (100 ml), dried (MgSO_4) and evaporated to leave a gum (3.5 g). This was dissolved in dry THF (25 ml) and treated with a 1 M solution of potassium *tert*-butoxide in THF (5 ml) and 2-chloro-*N*-methoxy-*N*-methyl-acetamide (1 g) added as a solution in THF (5 ml). The mixture was stirred at ambient temperature for 1 hr and partitioned between ethyl acetate (200 ml) and 2 M HCl (100 ml). The ethyl acetate extract was washed with water (2 x 100 ml), brine (100 ml), dried (MgSO_4) and evaporated to give the sub-titled compound as a yellow gum (3.32 g).

¹H NMR (CDCl_3) δ 7.98 (1H, dd), 7.94 (1H, s), 7.66 (1H, dd), 7.24 (1H, m), 5.21 (2H, s), 4.14 (2H, s), 3.87 (3H, s), 3.79 (2H, t), 3.76 (3H, s), 3.22 (3H, s), 0.87 (2H, t), 0.00 (9H, s).

c) 2,3-Dichloro-*N*-[3-methoxy-5-[[2-oxo-2-(2-thiazolyl)ethyl]thio]pyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide



Thiazole (0.17 g) was dissolved in dry THF (10 ml), cooled to -30 °C and stirred under an atmosphere of nitrogen. Butyl lithium (1.5 M, 1.5 ml) was added dropwise and the reaction was stirred for 30 mins and became a dark-orange colour. The product of Example 15 step b) (0.3 g) in THF (3 ml) was added dropwise and the reaction mixture was stirred between -20 to -10 °C for 2.5 hrs. The mixture was then poured into 2 M HCl (25 ml) and extracted into ethyl acetate (50 ml). The ethyl acetate extract was washed with water (2 x 20 ml), brine (20 ml), dried (MgSO_4) and evaporated to give a gum which was purified by silica gel chromatography, using hexane:ethyl acetate (2:1) as eluant to give the sub-titled compound as a yellow gum (0.1 g).


25

m/e 622 ($M+1$)⁺

¹H NMR (CDCl_3) δ 8.06 (1H, d), 7.96 (1H, s), 7.88 (1H, dd), 7.76 (1H, d), 7.65 (1H, dd), 7.25 (1H, m), 5.21 (2H, s), 4.75 (2H, s), 3.75 (2H, t), 3.53 (3H, s), 0.85 (2H, t), 0.01 (9H, s).

30

d) 2,3-Dichloro-N-[5-[[2-hydroxy-2-(2-thiazolyl)ethyl]thio]-3-methoxypyrazinyl]-benzenesulfonamide



The product of Example 15 step c) was dissolved in acetonitrile (3 ml) and treated with sodium triacetoxyborohydride and stirred at ambient temperature for 48 hr. The reaction mixture was treated with TFA (3 mls) for 30 mins and then partitioned between ethyl acetate (20 ml) and 2 M HCl (10 ml). The ethyl acetate extract was washed with water (2 x 20 ml), brine (20 ml), dried (MgSO_4) and evaporated to give a gum which was purified by silica gel chromatography, using hexane:ethyl acetate (1:1) as eluant to give the sub-titled compound as a yellow solid (0.03 g).


m/e 491/493/495 (M-1)⁻

¹H NMR (CDCl_3) δ 8.28 (1H, d), 7.6-7.7 (2H, m), 7.39 (1H, d), 7.76 (1H, d), 7.28 (1H, m), 4.25 (1H, m), 4.1 (3H, s), 3.99 (1H, d), 3.7-3.75 (1H, m), 3.41-3.49 (1H, m).

15


Example 16

2,3-Dichloro-N-[5-[[2-hydroxy-2-(1-methyl-1*H*-imidazol-2-yl)ethyl]thio]-3-methoxypyrazinyl]-benzenesulfonamide, potassium salt



20

a) 2,3-Dichloro-N-[3-methoxy-5-[[[(trimethylsilyl)methyl]thio]pyrazinyl]-N-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide




5

A solution of 2,3-dichloro-N-(5-chloro-3-methoxypyrazinyl)-N-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide (3.2g), trimethylsilylmethane thiol (1.0ml) and cesium carbonate (4.2g) in acetonitrile (50ml) was stirred under an atmosphere of nitrogen at room temperature for two hours. The reaction mixture was filtered and evaporated, and the residue purified by silica gel chromatography, using isohexane:ethyl acetate (10:1) as eluant, to give the sub-titled compound as a colourless oil (2.8g).

¹H NMR (CDCl₃) δ 7.95 (1H, d), 7.89 (1H, s), 7.64 (1H, d), 7.25 (1H, t), 5.24 (2H, s), 3.86 (3H, s), 3.82-3.76 (2H, m), 2.31 (2H, s), 0.89-0.84 (2H, m), 0.15 (9H, s), 0.01 (9H, s).

15

b) 2,3-Dichloro-N-[5-[[2-hydroxy-2-(1-methyl-1*H*-imidazol-2-yl)ethyl]thio]-3-methoxypyrazinyl]-N-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide




To a solution of 2,3-dichloro-N-[3-methoxy-5-[[[(trimethylsilyl)methyl]thio]pyrazinyl]-N-

20 [[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide (0.5g) and 1-methyl-2-imidazolecarboxaldehyde (94mg) in tetrahydrofuran (2ml) was added tetrabutylammonium fluoride (0.1ml of a 1M solution in THF), and the mixture stirred at room temperature

under an atmosphere of nitrogen for 5 minutes. The solvent was removed *in vacuo* and the residue purified by silica gel chromatography, eluting with 1:1 ethyl acetate:dichloromethane and ethyl acetate, to afford the sub-titled product as a colourless oil (0.12g).

⁵ ^1H NMR (CDCl_3) δ 7.97 (1H, d), 7.88 (1H, s), 7.65 (1H, d), 7.27 (1H, t), 6.96 (1H, s), 6.81 (1H, s), 5.22 (2H, s), 4.98 (1H, t), 3.88 (3H, s), 3.84-3.74 (5H, m), 3.68 (3H, s), 0.88-0.84 (2H, m), 0.00 (9H, s).

¹⁰ c) 2,3-Dichloro-N-[5-[[2-hydroxy-2-(1-methyl-1*H*-imidazol-2-yl)ethyl]thio]-3-methoxypyrazinyl]-benzenesulfonamide, potassium salt



A solution of the product from step b) (75mg) in dichloromethane (4ml) and trifluoroacetic acid (2ml) was stirred at room temperature for 30 minutes. The solvent was removed *in vacuo* and the residue purified by reverse phase preparative hplc, followed by treatment with one equivalent of potassium hydroxide, to give the title compound as a white solid. Yield 0.031g.


m/e 490/492 ($\text{M}+1$)⁺

²⁰ ^1H NMR (DMSO-d_6) δ 7.93 (1H, d), 7.60 (1H, d), 7.34 (1H, t), 7.19 (1H, s), 7.01 (1H, s), 6.74 (1H, s), 4.75 (1H, t), 3.79 (3H, s), 3.59 (3H, s), 3.48-3.42 (1H, m), 3.31-3.24 (1H, m).

Example 17


2,3-Dichloro-N-[5-[[2-hydroxy-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-benzenesulfonamide

²⁵



a) 2,3-Dichloro-N-[5-[[2-hydroxy-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-N-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide

5



Using the procedure of Example 16 step (b) 2,3-dichloro-N-[3-methoxy-5-
[[[trimethylsilyl)methyl]thio]pyrazinyl]-N-[[2-(trimethylsilyl)ethoxy]methyl]-

10 benzenesulfonamide (0.7g) was reacted with oxazole-2-carboxaldehyde (0.14g) in the presence of tetrabutylammonium fluoride (0.6ml of a 1M solution in THF) in tetrahydrofuran (3ml).


Yield 0.080g

¹H NMR (CDCl₃) δ 7.97 (1H, d), 7.91 (1H, s), 7.65 (1H, d), 7.61 (1H, s), 7.28 (1H, t),

15 7.08 (1H, s), 5.22 (2H, s), 5.14-5.09 (1H, m), 3.91 (3H, s), 3.80-3.64 (3H, m), 3.66-3.59 (1H, m), 3.55 (1H, br d), 0.88-0.83 (2H, m), 0.01 (9H, s).

b) 2,3-Dichloro-N-[5-[[2-hydroxy-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-benzenesulfonamide

20



Using the procedure of Example 16 step (c) the title compound was obtained by treating 2,3-dichloro-N-[5-[[2-hydroxy-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-N-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide (80mg) with trifluoroacetic acid (2ml) in dichloromethane (2ml).

Yield 0.056g


m/e 475/477 (M-1)⁺

¹H NMR (DMSO-d₆) 7.97 (1H, s), 7.93 (1H, d), 7.60 (1H, d), 7.34 (1H, t), 7.14 (1H, s), 7.10 (1H, s), 4.75 (1H, t), 3.79 (3H, s), 3.35-3.21 (2H, m).

10


Example 18

N-[5-[[2-Amino-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide



15


- a) 2,3-Dichloro-*N*-[5-[[2-chloro-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide



To a solution of 2,3-dichloro-N-[5-[[2-hydroxy-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-N-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide (0.35g) in dichloromethane (10ml) was added methanesulphonyl chloride (0.45ml) and triethylamine (1.2ml). The reaction was stirred at room temperature for two hours then diluted with ethyl acetate, washed with brine, dried over magnesium sulphate, filtered and evaporated to give the sub-titled compound as a yellow oil (0.41g).

m/e 627/629 (M+1)⁺

- 10 b) N-[5-[[2-Azido-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichloro-N-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide




- 15 A solution of 2,3-dichloro-N-[5-[[2-chloro-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-N-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide (0.41g) and sodium azide (0.11g) in dimethylformamide (10ml) was heated at 65°C for two hours. The cooled reaction mixture was diluted with diethyl ether and washed once with brine and three times with saturated aqueous ammonium chloride. The organic phase was dried over magnesium sulphate, filtered and evaporated to give the sub-titled compound as a yellow oil (0.24g).

m/e 502/504 ($M-130+1$)⁺ (loss of [(trimethylsilyl)ethoxy]methyl)

c) *N*-[5-[[2-Azido-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide


5



A solution of *N*-[5-[[2-azido-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichloro-*N*-[(2-(trimethylsilyl)ethoxy)methyl]-benzenesulfonamide (0.24g) in dichloromethane (10ml) and trifluoroacetic acid (3ml) was stirred at room temperature for one hour. The solvent was removed *in vacuo* and the residue purified by silica gel chromatography, eluting with 1:1 ethyl acetate:isohexane/0.5% acetic acid to give the sub-titled compound as a colourless oil (0.16g).

m/e 500/502 ($M-1$)

15 d) *N*-[5-[[2-Amino-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide



A solution of *N*-[5-[[2-azido-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide (0.16g) and triphenylphosphine (0.16g) in tetrahydrofuran (10ml) and water (2ml) was stirred at room temperature for 20 hours. Methanol (10ml) and 10% aqueous sodium hydroxide (2ml) were added and the reaction mixture stirred at room

5 temperature a further 24 hours. The reaction mixture was concentrated, acidified with 2M aqueous hydrochloric acid and extracted with dichloromethane (5x). The combined organic phases were dried over magnesium sulphate, filtered and evaporated to give a yellow solid which was purified by reverse phase preparative hplc to give the title compound as a white solid.

10 Yield 0.08g

m.p. 168-170°C

m/e 476/478 (M+1)⁺


¹H NMR (DMSO-d6) 8.12 (1H, s), 7.99 (1H, d), 7.68 (1H, d), 7.40 (1H, t), 7.26 (1H, s), 7.24 (1H, s), 4.59 (1H, m), 3.75 (3H, s), 3.57-3.52 (1H, m), 3.45-3.39 (1H, m).

15


Example 19


2,3-Dichloro-*N*-[5-[(2,3-dihydroxypropyl)thio]-3-methoxypyrazinyl]benzenesulfonamide

20



a) 2,3-Dichloro-*N*-[5-[(2,3-dihydroxypropyl)thio]-3-methoxypyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide.






Procedure as for Example 1 step d) using 3-mercaptopropane-1,2-diol. Yield 0.350g.
m/e 570 ($M+1^+$)

5

b) 2,3-Dichloro-N-[5-[(2,3-dihydroxypropyl)thio]-3-methoxypyrazinyl]benzenesulfonamide.



10

Procedure as for Example 1 step e) using 2,3-dichloro-N-[5-[(2,3-dihydroxypropyl)thio]-3-methoxypyrazinyl]-N-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide.

Yield 0.018g.


m/e 440 ($M+1^+$, 100%)

¹H NMR (DMSO) δ 11.27 (1H, bs), 8.02 (1H, d), 7.93 (1H, d), 7.67 (1H, s), 7.57 (1H, t), 3.89 (3H, s), 3.62 (1H, m), 3.40 (3H, m), 2.98 (1H, m).

MP 136-8°C


5 **Example 20**

2,3-Dichloro-N-[5-[(2-hydroxy-2-phenylethyl)thio]-3-methoxypyrazinyl]benzenesulfonamide



10

a) 2,3-Dichloro-N-[3-methoxy-5-[(2-oxo-2-phenylethyl)thio]pyrazinyl]-N-[{[2-(trimethylsilyl)ethoxy]methyl}benzenesulfonamide.




15

The product from Example 15 step a) (1.0 g) was dissolved in dry THF (20 ml) under an atmosphere of nitrogen and treated with a 1 M solution of potassium *tert*-butoxide in THF (2.5 ml), added dropwise. After stirring for 60 min the reaction was treated with phenacyl bromide (0.37 g) and allowed to stir for 20 hrs. The reaction mixture was poured into saturated aqueous ammonium chloride solution and extracted into ethyl acetate (x3). The combined ethyl acetate extracts were washed with water, brine and dried (MgSO₄) and evaporated to leave an oil. The residue was purified by silica gel chromatography, eluting with 1:4 ethyl acetate:isohexane, to afford the sub-titled product as a colourless oil (0.87g).

m/e 614 ($M+1^+$, 100%)

^1H NMR (CDCl_3) δ 8.02 (2H, m), 7.95 (2H, m), 7.63 (2H, m), 7.52 (2H, m), 7.25 (1H, m), 5.20 (2H, s), 4.59 (2H, s), 3.76 (2H, m), 3.56 (3H, s), 0.85 (2H, t), 0.00 (9H, s).

- 5 b) 2,3-Dichloro-*N*-[5-[(2-hydroxy-2-phenylethyl)thio]-3-methoxypyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide.




The product from Example 20 step a) (0.33 g) was dissolved in EtOH (5 ml) under an atmosphere of nitrogen and treated with sodium borohydride (0.042 g). The reaction was stirred for 24 hrs then poured into water and extracted into ethyl acetate (x3). The combined ethyl acetate extracts were washed with brine, dried (MgSO_4) and evaporated to afford the sub-titled product as a colourless oil (0.30g).

m/e 616 ($M+1^+$)

15

- c) 2,3-Dichloro-*N*-[5-[(2-hydroxy-2-phenylethyl)thio]-3-methoxypyrazinyl]benzenesulfonamide.



20

Procedure as for Example 1 step e) using the product from Example 20 step b) (0.30 g).

Yield 0.022g.


m/e 484 ($M-1^-$)

¹H NMR (DMSO) δ 8.02 (1H, dd), 7.94 (1H, dd), 7.58 (2H, m), 7.35 (2H, d), 7.17-7.29 (3H, m), 5.64 (1H, s), 4.75 (1H, t), 3.89 (3H, s), 3.27-3.46 (2H, m).

MP 141-3°C


5 **Example 21**

2,3-Dichloro-N-[5-[[2-hydroxy-2-(3-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]benzenesulfonamide



10

a) 2,3-Dichloro-N-[3-methoxy-5-[[2-oxo-2-(3-pyridinyl)ethyl]thio]pyrazinyl]-N-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide



15


Procedure as for Example 20 step a) using 3-(bromoacetyl)pyridine hydrobromide (0.70 g).

Yield 1.55g

m/e 615 (M+1⁺)

20

b) 2,3-Dichloro-N-[3-methoxy-5-[[2-oxo-2-(3-pyridinyl)ethyl]thio]pyrazinyl]benzenesulfonamide



Procedure as for Example 1 step e) using the product from Example 21 step a) (0.16 g).


Yield 0.122g.

m/e 483 (M-1)⁻

⁵ ¹H NMR (DMSO) δ 11.32 (1H, bs), 9.22 (1H, m), 8.81 (1H, m), 8.37 (1H, m), 8.02 (1H, dd), 7.93 (1H, dd), 7.74 (1H, s), 7.58 (2H, m), 4.84 (2H, s), 3.64 (3H, s).

MP 202-3°C

¹⁰ c) 2,3-Dichloro-N-[5-[[2-hydroxy-2-(3-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]benzenesulfonamide.



¹⁵ Procedure as for Example 20 step b) using the product from Example 21 step b) (0.10 g).

Yield 0.013g.


m/e 486 (M-1)⁻

¹H NMR (DMSO) δ 8.54 (1H, s), 8.39 (1H, d), 8.02 (1H, d), 7.92 (1H, d), 7.74 (1H, d), 7.57 (2H, m), 7.26 (1H, m), 5.81 (1H, d), 4.83 (1H, m), 3.89 (3H, s), 3.42 (2H, m).


²⁰ MP 188-90°C

Example 22

N-[5-[[2-Amino-2-(3-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide



a) 2,3-Dichloro-N-[5-[[2-hydroxy-2-(3-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-N-[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide.




Procedure as for Example 20 step b) using the product from Example 21 step a) (1.55 g).

Yield 0.92 g

m/e 617 ($M+1^+$)

b) 2,3-Dichloro-N-[5-[[2-chloro-2-(3-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-N-[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide




Procedure as for Example 18 step a) using the product from Example 22 step a) (0.74 g).

Yield 0.32 g

m/e 635 (M+1⁺)

⁵ ¹H NMR (CDCl₃) δ 8.58 (2H, m), 7.98 (1H, d), 7.83 (1H, s), 7.75 (1H, d), 7.66 (1H, d), 7.32 (2H, m), 5.22 (2H, s), 5.10 (1H, m), 4.03 (1H, m), 3.98 (3H, m), 3.78 (2H, m), 3.64 (1H, m), 0.86 (2H, m), 0.00 (9H, s).

c) *N*-[5-[[2-Azido-2-(3-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichloro-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide




Procedure as for Example 18 step b) using the product from Example 22 step b) (0.29g).

¹⁵ Yield 0.29g

m/e 642 (M+1⁺)

d) *N*-[5-[[2-Azido-2-(3-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide




Procedure as for Example 1 step e) using the product from Example 22 step c) (0.29 g).

Yield 0.23 g

5 m/e 510 (M-1)⁻

e) *N*-[5-[[2-Amino-2-(3-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide



10

Procedure as for Example 18 step d) using the product from Example 22 step d) (0.23 g).

Yield 0.025g.


m/e 484 (M-1)⁻

15 ¹H NMR (DMSO) δ 8.63 (1H, s), 8.53 (1H, d), 8.00 (1H, d), 7.87 (1H, d), 7.80 (1H, d), 7.48 (1H, t), 7.39 (2H, m), 4.53 (1H, t), 3.85 (3H, s), 3.55 (2H, m).

MP 175-8°C


Example 23

2,3-Dichloro-N-[5-[[2-hydroxy-2-(4-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]benzenesulfonamide



5

a) 2,3-Dichloro-N-[5-[[2-hydroxy-2-(4-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-N-[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide



10


Procedure as for Example 16 step b) using 4-pyridinecarboxaldehyde (0.066 ml).

Yield 0.180g

m/e 617 ($M+1^+$)

15

b) 2,3-Dichloro-N-[5-[[2-hydroxy-2-(4-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]benzenesulfonamide



Procedure as for Example 1 step e) using the product from Example 23 step a) (0.14 g).

Yield 0.055 g


m/e 485 (M-1)⁻

⁵ ¹H NMR (DMSO) δ 8.48 (2H, dd), 8.02 (1H, dd), 7.93 (1H, dd), 7.63 (1H, s), 7.57 (1H, t), 7.39 (2H, dd), 5.90 (1H, d), 4.81 (1H, m), 3.90 (3H, s), 3.46 (1H, dd), 3.35 (1H, dd).


MP 176-7°C

Example 24

¹⁰ **2,3-Dichloro-N-[5-[[2-hydroxy-2-(2-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]benzenesulfonamide**



¹⁵ a) 2,3-Dichloro-N-[5-[[2-hydroxy-2-(2-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-N-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide




Procedure as for Example 16 step b) using 2-pyridinecarboxaldehyde (0.066 ml).

Yield 0.10g

5 m/e 617 ($M+1^+$)

b) 2,3-Dichloro-N-[5-[[2-hydroxy-2-(2-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]benzenesulfonamide



10 Procedure as for Example 1 step e) using the product from Example 24 step a) (0.10 g).

Yield 0.016 g

m/e 485 ($M-1^-$)


¹H NMR (DMSO) δ 8.44 (1H, d), 8.02 (1H, d), 7.94 (1H, d), 7.73 (1H, t), 7.58 (2H, m),

15 7.49 (1H, d), 7.22 (1H, t), 5.82 (1H, s), 4.83 (1H, m), 3.91 (3H, s), 3.65 (1H, m), 3.35 (1H, m).

MP 143-5°C


Example 25

3-[[5-[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-(2R)-2-hydroxypropanoic acid, methyl ester



5

- a) 3-[[5-[(2,3-Dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxypyrazinyl]thio]-(2R)-2-hydroxypropanoic acid, methyl ester.




10

The product from Example 15 step a) (1.24 g) was dissolved in dry THF (10 ml) under an atmosphere of nitrogen and treated with a 1 M solution of potassium *tert*-butoxide in THF (2.3 ml), added dropwise. After stirring for 30 min the reaction was treated with (2S)-2-oxiranecarboxylic acid, methyl ester (1.0 ml) and allowed to stir for 20 hrs. The reaction mixture was poured into saturated aqueous ammonium chloride solution and extracted into ethyl acetate (x3). The combined ethyl acetate extracts were washed with water, brine and dried ($MgSO_4$) and evaporated to leave an oil. The residue was purified by silica gel chromatography, eluting with 1:1 ethyl acetate:isohexane, to afford the sub-titled product as a colourless oil (0.23g).

m/e 598 ($M+1^+$)

b) 3-[[5-[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-(2R)-2-hydroxypropanoic acid, methyl ester.



5

Procedure as for Example 1 step e) using the product from Example 25 step a) (0.23 g). Yield 0.012g.


m/e 466 (M-1)⁻

¹H NMR (DMSO) δ 7.95 (1H, dd), 7.61 (1H, dd), 7.35 (1H, t), 7.19 (1H, s), 4.18 (1H, t), 3.80 (3H, s), 3.50 (3H, s), 3.21 (1H, dd), 3.04 (1H, dd).

MP 88-90°C


Example 26

N-[5-[[2-Amino-2-(2-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide



a) 2,3-Dichloro-*N*-[5-[[2-chloro-2-(2-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-*N*-[[2-

20 (trimethylsilyl)ethoxy]methyl]benzenesulfonamide




Procedure as for Example 18 step a) using the product from Example 24 step a) (0.70 g).

Yield 0.72 g

m/e 635 ($M+1^+$)

5

b) *N*-[5-[[2-Azido-2-(2-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichloro-*N*-[(2-(trimethylsilyl)ethoxy)methyl]benzenesulfonamide



10


Procedure as for Example 18 step b) using the product from Example 26 step a) (0.72g).

Yield 0.70 g

m/e 642 ($M+1^+$)

15

c) *N*-[5-[[2-Azido-2-(2-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichloro benzenesulfonamide




Procedure as for Example 1 step e) using the product from Example 26 step b) (0.70 g).

Yield 0.34 g

m/e 510 (M-1)⁺

⁵ ¹H NMR (DMSO) δ 8.57 (1H, m), 8.04 (1H, d), 7.94 (1H, d), 7.81 (1H, t), 7.65 (1H, s), 7.58 (1H, t), 7.47 (1H, d), 7.35 (1H, m), 4.94 (1H, t), 3.94 (3H, s), 3.75 (1H, m), 3.65 (1H, m).

d) *N*-[5-[[2-Amino-2-(2-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenesulfonamide



Procedure as for Example 18 step d) using the product from Example 26 step c) (0.15 g).

Yield 0.018g.

m/e 484 (M-1)⁺


¹H NMR (DMSO) δ 8.54 (1H, d), 7.95 (1H, d), 7.76 (1H, t), 7.62 (1H, d), 7.45 (1H, d), 7.33 (2H, m), 7.19 (1H, s), 4.42 (1H, t), 3.79 (3H, s), 3.30 (2H, m).

MP 172-4°C

Example 27


***N*-[5-[[2-Amino-2-(1-methyl-1*H*-imidazol-2-yl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide**

5



a) 2,3-Dichloro-*N*-[5-[[2-chloro-2-(1-methyl-1*H*-imidazol-2-yl)ethyl]thio]-3-methoxypyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide

10




Procedure as for Example 18 step a) using the product from Example 16 step b) (0.44 g).

Yield 0.45 g

m/e 638 ($M+1^+$)

15

b) *N*-[5-[[2-Azido-2-(1-methyl-1*H*-imidazol-2-yl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichloro-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide




Procedure as for Example 18 step b) using the product from Example 27 step a) (0.72g).

Yield 0.455 g

5 m/e 645 ($M+1^+$)

c) *N*-[5-[[2-Azido-2-(1-methyl-1*H*-imidazol-2-yl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide




10 Procedure as for Example 1 step e) using the product from Example 27 step b) (0.45 g).

Yield 0.36 g

m/e 513 ($M-1^-$)

15 d) *N*-[5-[[2-Amino-2-(1-methyl-1*H*-imidazol-2-yl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide



Procedure as for Example 18 step d) using the product from Example 27 step c) (0.36 g). Yield 0.038g.


5 m/e 489 ($M+1^+$)

^1H NMR (DMSO) δ 8.04 (1H, d), 7.94 (1H, d), 7.59 (2H, m), 7.05 (1H, s), 6.84 (1H, s), 4.77 (1H, t), 3.95 (3H, s), 3.58 (3H, s), 3.5-3.7 (2H, m).

MP 187-9°C


10 **Example 28**

(2*R*)-2-Amino-3-[[3-chloro-5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-*N*-methylpropanamide



15

a) *N,N'*-bis[(1,1-dimethylethoxy)carbonyl]-*N,N'*-dimethyl-L-cystinamide




A solution of *N,N'*-bis[(1,1-dimethylethoxy)carbonyl]-L-cystine (4.08g) in tetrahydrofuran (100 mL) was cooled to 0°C under nitrogen and isobutyl chloroformate (2.9 mL) was added dropwise followed by triethylamine (3.1 ml) dropwise. After 30 minutes at 0°C a

- 5 2.0M solution of methylamine in THF (20 ml) was added. After stirring at room temperature for 24 hours, the reaction mixture was poured into saturated ammonium chloride solution and extracted with ethyl acetate (x3). The combined extracts were washed with saturated brine, dried (MgSO_4) and the solvent was evaporated to afford the subtitled product as a white solid (2.6 g).

10 m/e 467 ($M+1^+$)

b) [(1*R*)-1-(Mercaptomethyl)-2-(methylamino)-2-oxoethyl]carbamic acid, 1,1-dimethylethyl ester




- 15 To a suspension of the product from Example 28 step a) (2.15 g) in 1,1,1-trifluoroethanol (5 mL) and water (0.6 ml) was added dropwise tributylphosphine (2.25 ml) followed by triethylamine (0.10 ml). After stirring at room temperature for 24 hours, ethyl acetate and silica were added and the mixture evaporated. The residue was purified by silica gel chromatography, eluting with 1:1 ethyl acetate:isohexane, to afford the sub-titled product
- 20 as a white solid (1.85 g).

m/e 233 ($M-1^-$)

^1H NMR (CDCl_3) δ 6.33 (1H, bs), 5.38 (1H, bs), 4.32 (1H, bs), 3.15 (1H, m), 2.85 (3H, d), 2.70 (1H, m), 1.55 (1H, t), 1.46 (9H, s).

c) [(1*R*)-1-[[[3-Chloro-5-[(2,3-dichlorophenyl)sulfonyl]thio]methyl]-2-(methylamino)-2-oxoethyl]carbamic acid, 1,1-dimethylethyl ester




5

Procedure as for Example 2 step a) using *N*-(5-bromo-6-chloro-3-methoxypyrazinyl)-2,3-dichloro-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide (0.25 g) and [(1*R*)-1-(mercaptomethyl)-2-(methylamino)-2-oxoethyl]carbamic acid, 1,1-dimethylethyl ester (0.105 g).

10 Yield 0.24 g.

d) (2*R*)-2-Amino-3-[[3-chloro-5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-*N*-methylpropanamide



15 Procedure as for Example 1 step e) using the product from Example 28 step c) (0.24 g).

Yield 0.03 g.


m/e 498 (M-1)⁺

¹H NMR (DMSO) δ 8.25 (1H, d), 8.02 (1H, d), 7.63 (1H, d), 7.60 (2H, bs), 7.37 (1H, t), 3.80 (4H, m), 3.30 (2H, m), 2.55 (3H, d).

20 MP 150-5°C

Example 29


(2*R*)-2-Amino-3-[[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxy-3-methylpyrazinyl]thio]-*N*-methylpropanamide



5

a) [(1*R*)-1-[[[5-[(2,3-Dichlorophenyl)sulfonyl][[2-(trimethylsilyl)ethoxy]methyl]amino]-6-methoxy-3-methylpyrazinyl]thio]methyl]-2-(methylamino)-2-oxoethyl]carbamic acid, 1,1-dimethylethyl ester

10




Procedure as for Example 2 step a) using the product from Example 11 step e) (0.25 g) and [(1*R*)-1-(mercaptomethyl)-2-(methylamino)-2-oxoethyl]carbamic acid, 1,1-dimethylethyl ester (0.11 g).

15

Yield 0.32 g.

b) (2*R*)-2-Amino-3-[[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxy-3-methylpyrazinyl]thio]-*N*-methylpropanamide



Procedure as for Example 1 step e) using the product from Example 29 step a) (0.32 g).

Yield 0.115 g.


m/e 478 (M-1)⁻

⁵ ¹H NMR (DMSO) δ 8.06 (1H, dd), 7.80 (1H, m), 7.58 (1H, dd), 7.35 (1H, t), 3.77 (3H, s), 3.27 (2H, m), 2.93 (1H, m), 2.50 (3H, d), 1.87 (3H, s).


MP 68-80°C

Example 30

¹⁰ *N*-[5-[[2-Amino-2-(2-thiazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide



¹⁵ a) 2,3-Dichloro-*N*-[5-[[2-hydroxy-2-(2-thiazolyl)ethyl]thio]-3-methoxypyrazinyl]-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide




Procedure as for Example 16 step (b) using thiazole-2-carboxaldehyde (1.0 g).

Yield 0.75 g

5 m/e 623 (M+1⁺)

b) 2,3-Dichloro-N-[5-[[2-chloro-2-(2-thiazolyl)ethyl]thio]-3-methoxypyrazinyl]-N-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide



10


Procedure as for Example 18 step a) using the product from Example 30 step a) (0.75 g).

Yield 0.77 g

m/e 639 (M+1⁺)

15

c) N-[5-[[2-Azido-2-(2-thiazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichloro-N-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide




Procedure as for Example 18 step b) using the product from Example 30 step b) (0.77 g).

Yield 0.78 g

5 m/e 648 ($M+1^+$)

d) *N*-[5-[[2-Azido-2-(2-thiazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide




10 Procedure as for Example 1 step e) using the product from Example 30 step c) (0.78 g).

Yield 0.62 g

m/e 516 ($M-1$)

15 e) *N*-[5-[[2-Amino-2-(2-thiazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide



Procedure as for Example 18 step d) using the product from Example 30 step d) (0.62 g). Yield 0.15 g.


5 m/e 492 ($M+1^+$)

^1H NMR (DMSO) δ 8.16 (2H, bs), 7.98 (1H, d), 7.85 (1H, d), 7.77 (1H, d), 7.68 (1H, d), 7.41 (1H, t), 7.32 (1H, s), 4.77 (1H, t), 4.09 (1H, bs), 3.78 (3H, s), 3.4-3.6 (2H, m).

MP 168-9°C

10 **Example 31**

***N*-[5-[(2*R*)-2-Amino-3-hydroxypropyl]oxy]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide, monohydrochloride**



15

2,3-Dichloro-*N*-(5-chloro-3-methoxypyrazinyl)-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide (0.25g) and (4*S*)-4-(hydroxymethyl)-2,2-dimethyl-3-oxazolidinecarboxylic acid 1,1-dimethylethyl ester (0.142g) were dissolved in dry 1,2-dimethoxyethane (5ml) under an atmosphere of nitrogen and treated with sodium hydride (60% suspension in oil, 0.026g). After stirring at ambient temperature overnight the reaction was poured into water and extracted twice with ethyl acetate. The organic extracts

20

were washed with brine, dried (MgSO_4) and evaporated to give a pale yellow oil (0.413g). The oil was dissolved in dichloromethane (5ml) and treated with trifluoroacetic acid (1ml). After stirring at ambient temperature overnight, methanol (5ml) was added and the solution was stirred for 1 hour. The mixture was diluted with dichloromethane, flash silica (5g) 5 was added and the solvents were removed *in vacuo*. The resulting powder was purified by flash chromatography on silica, eluting with 5% and 10% methanol in dichloromethane to afford a colourless residue (0.164g). After dissolving the residue in methanol and treating it with 4M HCl solution in 1,4-dioxane (1ml), the solvents were removed *in vacuo*. Trituration with diethyl ether afforded a solid that was removed by filtration and dried *in 10 vacuo* at 40° to give the title compound as an off-white powder.

Yield 0.108g

m.p. 130-150°C (decomposes)

m/e 423/425 ($\text{M}+1$)⁺


¹H NMR (D_2O) 8.06 (1H, m), 7.95 (1H, m), 7.55 (2H, m), 4.69 (1H, m), 4.57 (1H, m), 4.02

15 (1H, m), 3.95 (3H, s), 3.90 (2H, m).

Example 32

2,3-Dichloro-N-[5-[(2S)-2,3-dihydroxypropyl]oxy]-3-methoxypyrazinyl]-benzenesulfonamide

20



2,3-Dichloro-N-(5-chloro-3-methoxypyrazinyl)-N-[(2S)-2,3-dihydroxypropyl]benzenesulfonamide (0.25g) and (4R)-2,2-dimethyl-1,3-dioxolane-4-methanol (0.079g) 25 were dissolved in dry 1,2-dimethoxyethane (5ml) under an atmosphere of nitrogen and treated with sodium hydride (60% suspension in oil, 0.026g). After stirring at ambient temperature overnight the reaction was poured into water and extracted twice with ethyl acetate. The organic extracts were washed with brine, dried (MgSO_4) and evaporated to give a colourless gum (0.230g). The gum was dissolved in dichloromethane (5ml) and

treated with trifluoroacetic acid (1ml). After stirring at ambient temperature for 2 hours, methanol (5ml) was added and the solution was stirred for 2.5 hours. More trifluoroacetic acid (2ml) was then added and the mixture was stirred for a further 3 hours. Flash silica (5g) was added and the the solvents were removed *in vacuo*. The resulting powder was
 5 purified by flash chromatography on silica, eluting with 5% methanol in dichloromethane to afford a white foam (0.055g). Further purification by reversed phase preparative hplc gave the title compound as a white foam.

Yield 0.026g


m/e 424/426 (M+1)⁺

10 ¹H NMR (DMSO-d6) 7.95 (1H, m), 7.85 (1H, m), 7.49 (1H, m), 7.34 (1H, s), 4.93 (1H, d),
 4.63 (1H, t), 4.23 (1H, m), 4.08 (1H, m), 3.80 (3H, s), 3.76 (1H, m), 3.40 (2H, m).

Example 33

2,3-Dichloro-N-[5-[(2R)-2,3-dihydroxypropyl]oxy]-3-methoxypyrazinyl-

15 benzenesulfonamide



2,3-Dichloro-N-(5-chloro-3-methoxypyrazinyl)-N-[[2-(trimethylsilyl)ethoxy]methyl]-

20 benzenesulfonamide (0.25g) and (4S)-2,2-dimethyl-1,3-dioxolane-4-methanol, (0.080g) were dissolved in dry 1,2-dimethoxyethane (5ml) under an atmosphere of nitrogen and treated with sodium hydride (60% suspension in oil, 0.026g). After stirring at ambient temperature overnight the reaction was poured into water and extracted twice with ethyl acetate. The organic extracts were washed with brine, dried ($MgSO_4$) and evaporated to give a colourless gum (0.346g). The gum was dissolved in dichloromethane (5ml) and treated with trifluoroacetic acid (1ml). After stirring at ambient temperature for 2 hours, methanol (5ml) was added and the solution was stirred for 2.5 hours. More trifluoroacetic acid (2ml) was then added and the mixture was stirred for a further 3 hours. Flash silica
 25 (5g) was added and the the solvents were removed *in vacuo*. The resulting powder was

purified by flash chromatography on silica, eluting with 4% methanol in dichloromethane to afford a white foam (0.060g). Further purification by reversed phase preparative hplc gave the title compound as a white foam.


Yield 0.035g

m/e 424/426 (M+1)⁺

¹H NMR (DMSO-d₆) 7.94 (1H, m), 7.74 (1H, m), 7.42 (1H, m), 7.18 (1H, s), 4.89 (1H, d), 4.61 (1H, t), 4.16 (1H, m), 4.00 (1H, m), 3.78 (3H, s), 3.75 (1H, m), 3.39 (2H, m).

Example 34

¹⁰ *N*-[5-[(2*R*)-2-Amino-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide



¹⁵ *N*-(5-Bromo-3-methoxypyrazinyl)-2,3-dichloro-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide (0.25g), [(1*R*)-2-mercaptopo-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-carbamic acid 1,1-dimethylethyl ester (0.133g) and caesium carbonate (0.166g) in acetonitrile (5ml) were stirred at ambient temperature overnight. The reaction was poured into a mixture of water and brine and extracted twice with ethyl acetate. The organic extracts were washed with brine, dried ($MgSO_4$) and evaporated to give a yellow gum (0.385g). The gum was dissolved in dichloromethane (5ml) and treated with trifluoroacetic acid (2.5ml). After stirring at ambient temperature for 1 hour the solvents were removed *in vacuo* and the residue was purified by reversed phase preparative hplc to afford the title compound as a pale orange powder.


²⁰ Yield 0.062g

m/e 491/493 (M+1)⁺

¹H NMR (DMSO-d6) 8.05 (1H, m), 7.95 (1H, m), 7.63 (1H, s), 7.59 (1H, m), 5.11 (1H, t), 3.97 (3H, s), 3.78 (2H, broad d), 2.26 (3H, s).

Example 35

5 *N*-[5-[(2*R*)-2-Amino-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]thio]-3-methoxy-6-methylpyrazinyl]-2,3-dichlorobenzenesulfonamide




10 *N*-(5-Bromo-3-methoxy-6-methylpyrazinyl)-2,3-dichloro-*N*-[[2-(trimethylsilyl)ethoxy]methyl]-benzenesulfonamide (0.251g), [(1*R*)-2-mercaptop-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-carbamic acid 1,1-dimethylethyl ester (0.143g) and caesium carbonate (0.184g) in acetonitrile (5ml) were stirred at ambient temperature overnight. More [(1*R*)-2-mercaptop-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-carbamic acid 1,1-dimethylethyl ester (0.082g), caesium carbonate (0.089g) and acetonitrile (5ml) were added and the mixture was stirred at ambient temperature for 2 more days. The reaction was poured into a mixture of water and brine and extracted three times with ethyl acetate. The organic extracts were washed with brine, dried ($MgSO_4$) and evaporated to give a brown gum (0.441g). The gum was dissolved in dichloromethane (5ml) and treated with trifluoroacetic acid (2.5ml). After stirring at ambient temperature for 2.75 hours, flash silica (5g) was added and the solvents were removed *in vacuo*. The resulting powder was purified by flash chromatography on silica, eluting with 2% and 5% methanol in dichloromethane to afford a pale brown foam (0.095g). Further purification by reversed phase preparative hplc afforded the titled compound as a pale yellow powder.

15 Yield 0.021g
20 m/e 505/507 ($M+1$)⁺

¹H NMR (DMSO-d6) 8.09 (1H, d), 7.83 (1H, d), 7.52 (1H, t), 4.48 (1H, t), 3.85 (3H, s), 3.45-3.60 (2H, m), 2.22 (3H, s), 1.95 (3H, s).

Example 36

5 *N*-[5-[(2*R*)-2-Amino-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]thio]-6-chloro-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide



10 A solution of *N*-(5-Bromo-6-chloro-3-methoxypyrazinyl)-2,3-dichloro-*N*-[[2-(trimethylsilyl)ethoxy]methyl]benzenesulfonamide (0.203g), [(1*R*)-2-mercaptop-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-carbamic acid 1,1-dimethylethyl ester (0.158g) and *N,N*-diisopropylethylamine (0.060ml) in *N*-methylpyrrolidinone (3ml) was stirred at 50° overnight. The reaction mixture was concentrated *in vacuo* to give a brown residue that was dissolved in dichloromethane (5ml) and treated with trifluoroacetic acid (2.5ml). After stirring at ambient temperature for 1.25 hours the solvents were removed *in vacuo* and the residue was purified by reversed phase preparative hplc to afford a white solid. Recrystallisation from aqueous methanol gave the title compound an off-white powder.

15 Yield 0.035g

20 m/e 527 (M+1)⁺

¹H NMR (DMSO-d6) 8.24 (1H, br), 8.02 (1H, d), 7.70 (1H, d), 7.42 (1H, t), 4.94 (1H, t), 3.86 (3H, s), 3.66 (1H, m), 3.53 (1H, m), 2.29 (3H, s).

Pharmacological Analysis

25

FMAT Whole cell binding assay

Cells

5 CHO-K1 cells stably expressing the human recombinant CCR4 receptor (Euroscreen; Brussels, Belgium) were cultured in NUT.MIX.F_12(HAM) medium with glutamax-1, containing 10% (v/v) foetal bovine serum and 400 µg ml⁻¹ geneticin.

10 Cells were harvested at approximately 70% confluence by treatment with a cell dissociation buffer, and seeded at 5x10³ cells/100µl culture medium into wells of a black Costar clear-bottomed 96-well microtitre plates. Plates were incubated overnight at 37°C in 5% CO₂ and used the following day.

ASSAY

15 Before use, the cell plates were washed twice with 100 µl Hanks balanced salt solution (HBSS). To each well was then added 65µl of HBSS, 10 µL of 10% DMSO in HBSS ± test compound and then 25 µL of 2.8 nM FB-MDC (Applied Biosystems). This fluorescent probe was prepared from a 10µM stock in 0.08% (v/v) TFA/16% (v/v) acetonitrile, diluted into HBSS.

20 After two hours incubation in the dark at room temperature, the plates were analysed in an FMAT8100 reader (Applied Biosystems) to measure fluorescence that was associated with binding of FB-MDC to the cells. Compound activity was determined as an pIC₅₀ [log(concentration of compound that results in 50% inhibition)], comparing fluorescence in
25 control and background wells.

Typical Data

Fluorescence (ctrl) = 1200

30 Fluorescence (bkg) = 0

The compounds of the examples all have a pIC₅₀ of greater than 5.0.

Data for specific compounds is given below.


35 Mean

Example 4 pIC₅₀ 6.2

Example 15 pIC₅₀ 6.4

CLAIMS

1. A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof:



in which:

Ar¹ is phenyl or thienyl, each of which is optionally substituted by one to three substituents R¹, R² and R³ selected from halogen, cyano, CF₃, OCF₃, OC₁₋₆ alkyl or C₁₋₆ alkyl;

R⁴ is C₁₋₆ alkoxy where the alkyl group may form a 3-6 membered saturated ring or may be substituted with 1-3 fluorine atoms or a cyano group; or

OC₁₋₆ alkylR¹¹, or OC₂₋₆ alkyl-X-R¹¹ where the alkyl group may form a 3-6 membered saturated ring and is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR¹⁴R¹⁵, SR¹³, S(O)₂R¹³, S(O)R¹³ or COR¹³;

one of R⁵ or R⁶ is XCH₂C₁₋₄ alkyl where the alkyl group is substituted at any position by the two groups R¹¹ and either NR¹⁴R¹⁵ or hydroxy, or R⁵/R⁶ is XR¹⁶ where R¹⁶ is a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen or sulphur and optionally substituted with 1-3 groups selected from hydroxy, cyano, halogen and =O, and R¹⁶ is substituted by R¹¹;

and the other is hydrogen, halogen, amino, NHC₁₋₆ alkyl, N(C₁₋₆ alkyl)₂, C₁₋₆ alkoxy or C₁₋₆ alkyl optionally substituted by one or more fluoro or hydroxyl groups;

X is NR¹³, O, S, S(O), S(O)₂, or a bond;

R¹¹ is an aryl group or a 5-7 membered heteroaromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, which aryl group or heteroaromatic ring can be optionally substituted by 1-3 groups selected from halogen, C(O)NR¹⁴R¹⁵, C(O)OR¹², hydroxy, =O, =S, CN, NO₂, COR¹³, NR¹⁴R¹⁵, X(CH₂)qNR¹⁴R¹⁵, (CH₂)nNR¹⁴R¹⁵, (CH₂)nOH, SR¹³, S(O)R¹³, S(O)₂R¹³

C_{1-6} alkyl-X- C_{1-6} alkyl, C_{1-6} alkyl or C_{1-6} alkoxy where the alkyl group may form a 3-6 membered ring or is optionally substituted with 1-3 groups selected from hydroxy, halogen, $NR^{14}R^{15}$, SR^{13} , $S(O)R^{13}$, $S(O)_2R^{13}$; or

5 R^{11} is $C(O)NR^{14}R^{15}$, $C(O)OR^{12}$, CH_2OR^{12}

R^{12} and R^{13} are independently hydrogen or C_{1-6} alkyl where the alkyl group may be substituted with 1-3 fluorine atoms or may form a saturated 3-6 membered ring;

10 R^{14} and R^{15} are independently hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, $(CH_2)qOH$ or $(CH_2)qNH_2$,

15 or R^{14} and R^{15} together with the nitrogen atom to which they are attached form a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen and sulphur and optionally substituted by C_{1-6} alkyl, C_{1-6} alkyl-OH, or hydroxy; and

n is 1, 2, 3, 4 or 5; and

q is 2, 3, 4, 5 or 6,

20

- provided that where X is a bond then R^5/R^6 is not $XCH_2C_{1-4}\text{alkyl}R^{11}$.

2. A compound according to claim 1 in which Ar^1 is phenyl optionally substituted by one or more halogen atoms.

25

3. A compound according to claim 1 or 2 in which R^4 is methoxy.

4. A compound according to any one of claims 1 to 3 in which R^5 is $XCH_2CH(R^{11})NR^{14}R^{15}$ where R^{11} is CO_2Me or $CONHMe$ or a 5 or 6-membered heterocycle and $NR^{14}R^{15}$ is NH_2 or $NHMe$ and X is S or O.

30 5. A compound according to any one of claims 1 to 4 in which R^6 is hydrogen, chloro or methyl.

35

6. A compound according to any one of claims 1 to 5 in which X is NR^{13} , O, S, $S(O)$ or $S(O)_2$.

7. A compound of formula (I) selected from:

S-[5-[[2,3-Dichlorophenyl]sulfonyl]amino]-6-methoxypyrazinyl]-D-cysteine, methyl ester

- S-[5-[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine, methyl ester
S-[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine
(2*R*)-2-amino-3-[[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]propanamide
5 (2*R*)-2-amino-3-[[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]propanamide
(2*R*)-2-amino-3-[[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-*N,N*-dimethylpropanamide
N-[5-[(2*R*)-2-amino-3-hydroxypropyl]thio]-3-methoxypyrazinyl]-2,3-dichloro
10 benzenesulfonamide
S-[3-chloro-5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine, methyl ester
S-[3-chloro-5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-cysteine
N-[5-[(2*R*)-2-amino-3-hydroxypropyl]thio]-6-chloro-3-methoxypyrazinyl]-2,3-
15 dichlorobenzenesulfonamide
S-[5-[(2,3-Dichlorophenyl)sulfonyl]amino]-6-methoxy-3-methylpyrazinyl]-L-cysteine, methyl ester
S-[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxy-3-methylpyrazinyl]-L-cysteine,
N-(2-Aminoethyl)-S-[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]-L-
20 cysteine, ethyl ester
N-[5-[(2*R*)-2-amino-2-phenylethoxy]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide
2,3-Dichloro-N-[5-[(2-hydroxy-2-(2-thiazolyl)ethyl]thio]-3-methoxypyrazinyl]-benzenesulfonamide,
25 2,3-Dichloro-N-[5-[(2-hydroxy-2-(1-methyl-1*H*-imidazol-2-yl)ethyl]thio]-3-methoxypyrazinyl]-benzenesulfonamide, potassium salt
2,3-Dichloro-N-[5-[(2-hydroxy-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-benzenesulfonamide
30 N-[5-[(2-amino-2-(2-oxazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide
2,3-dichloro-N-[5-[(2,3-dihydroxypropyl)thio]-3-methoxypyrazinyl]-benzenesulfonamide
2,3-dichloro-N-[5-[(2-hydroxy-2-phenylethyl)thio]-3-methoxypyrazinyl]-benzenesulfonamide
35 2,3-dichloro-N-[5-[(2-hydroxy-2-(3-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-benzenesulfonamide

N-[5-[[2-amino-2-(3-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichloro benzenesulfonamide

2,3-dichloro-*N*-[5-[[2-hydroxy-2-(4-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]benzenesulfonamide

5 2,3-dichloro-*N*-[5-[[2-hydroxy-2-(2-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]benzenesulfonamide

3-[[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-(2*R*)-2-hydroxypropanoic acid, methyl ester

10 *N*-[5-[[2-amino-2-(2-pyridinyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide

N-[5-[[2-amino-2-(1-methyl-1*H*-imidazol-2-yl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide

(2*R*)-2-amino-3-[[3-chloro-5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxypyrazinyl]thio]-*N*-methylpropanamide

15 (2*R*)-2-amino-3-[[5-[(2,3-dichlorophenyl)sulfonyl]amino]-6-methoxy-3-methylpyrazinyl]thio]-*N*-methylpropanamide

N-[5-[[2-amino-2-(2-thiazolyl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide

N-[5-[(2*R*)-2-Amino-3-hydroxypropyl]oxy]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide, monohydrochloride

2,3-Dichloro-*N*-[5-[(2*S*)-2,3-dihydroxypropyl]oxy]-3-methoxypyrazinyl]-benzenesulfonamide

2,3-Dichloro-*N*-[5-[(2*R*)-2,3-dihydroxypropyl]oxy]-3-methoxypyrazinyl]-benzenesulfonamide

25 *N*-[5-[(2*R*)-2-Amino-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]thio]-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide

N-[5-[(2*R*)-2-Amino-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]thio]-3-methoxy-6-methylpyrazinyl]-2,3-dichlorobenzenesulfonamide

30 *N*-[5-[(2*R*)-2-Amino-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]thio]-6-chloro-3-methoxypyrazinyl]-2,3-dichlorobenzenesulfonamide and pharmaceutically acceptable salts thereof.

8. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed any one of claims 1 to 7 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

5 9. A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 7 for use in therapy.

10. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 to 7 in the manufacture of a medicament for use in therapy.

10 11. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 to 7 in the manufacture of a medicament for use as a CCR4 antagonist.

15 12. A compound of formula (I) for use in the treatment of a disease where modulation of CCR4 activity is beneficial.

13. A method of treating a chemokine mediated disease wherein the chemokine binds to one or more chemokine receptors, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed any one of claims 1 to 7.

20 14. A method according to claim 13 in which the chemokine receptor belongs to the CCR chemokine receptor subfamily.


25 15. A method according to claim 13 or 14 in which the chemokine receptor is the CCR4 receptor.

16. A method of treating an inflammatory disease in a patient suffering from, or at risk of, 30 said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 7.

17. A method according to claim 16 wherein the disease is asthma.

35 18. A process for the preparation of a compound of formula (I) which comprises either

(a) reacting of a compound of formula (II):



(II)


, wherein Ar^1 , R^4 and R^6 are as defined above, P is a protecting group and X is a leaving group,

with a compound $\text{R}^5\text{-H}$ in the presence of a base, and optionally thereafter,

- removing any protecting groups
- forming a pharmaceutically acceptable salt:


10

(b) where the compound of formula (I) is of formula (Ia)



15

, wherein Ar^1 , R^4 , R^6 and R^{11} are as defined above, reacting a compound of formula (X)



20

with a reducing agent such as triphenylphosphine in the presence of water, and optionally thereafter,

- removing any protecting groups
- forming a pharmaceutically acceptable salt.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2004/000850

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: **13-17**
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2004/000850

Claims 13-17 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2004/000850

A. CLASSIFICATION OF SUBJECT MATTER

**IPC7: C07D 241/20, C07D 403/12, C07D 417/12, C07D 401/12, C07D 413/12,
A61K 31/4965, A61K 31/497, A61P 11/06, A61P 29/00**
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, CHEM. ABS DATA, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 0224665 A1 (ACTELION PHARMACEUTICALS LTD), 28 March 2002 (28.03.2002) --	1-18
A	WO 0230357 A2 (CHEMOCENTRYX, INC.), 18 April 2002 (18.04.2002) --	1-18
A	US 6420567 B1 (CHENGDE WU ET AL), 16 July 2002 (16.07.2002) --	1-18
PX	WO 03051870 A1 (ASTRAZENECA AB), 26 June 2003 (26.06.2003) --	1-18

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

29 Sept 2004

Date of mailing of the international search report

05 -10- 2004

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. + 46 8 666 02 86

Authorized officer
Anna Sjölund/EÖ
Telephone No. + 46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2004/000850

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
PX	WO 03059893 A1 (ASTRAZENECA AB), 24 July 2003 (24.07.2003) -- -----	1-18

INTERNATIONAL SEARCH REPORT

Information on patent family members

03/09/2004

International application No.

PCT/SE 2004/000850

WO	0224665	A1	28/03/2002	AU	1217102 A	02/04/2002
				BR	0114082 A	22/07/2003
				CA	2423351 A	28/03/2002
				EP	1322624 A	02/07/2003
				HU	0303364 A	01/03/2004
				IL	154364 D	00/00/0000
				NO	20031332 A	24/03/2003
				US	20040102464 A	27/05/2004

WO	0230357	A2	18/04/2002	AU	1346602 A	22/04/2002
				AU	1346702 A	22/04/2002
				CA	2425259 A	18/04/2002
				US	20020132836 A	19/09/2002
				US	20020173524 A	21/11/2002
				US	20040039035 A	26/02/2004
				WO	0230358 A	18/04/2002

US	6420567	B1	16/07/2002	US	6632829 B	14/10/2003
				US	20020091272 A	11/07/2002
				US	20030208084 A	06/11/2003
				AP	9901471 D	00/00/0000
				AT	270669 T	15/07/2004
				AU	736269 B	26/07/2001
				AU	4505997 A	17/04/1998
				BR	9711550 A	18/01/2000
				CA	2261760 A	02/04/1998
				CN	1231664 A	13/10/1999
				CZ	9900854 A	16/06/1999
				DE	69729803 D	00/00/0000
				EA	4146 B	00/00/0000
				EP	0946552 A,B	06/10/1999
				EP	1342721 A	10/09/2003
				IL	128145 D	00/00/0000
				JP	2000507607 T	20/06/2000
				JP	2002308875 A	23/10/2002
				KR	2000048681 A	25/07/2000
				NO	991388 A	27/05/1999
				NZ	334797 A	23/02/2001
				OA	11024 A	06/11/2001
				PL	332323 A	30/08/1999
				SK	36599 A	14/02/2000
				TR	9900705 T	00/00/0000
				US	5962490 A	05/10/1999
				US	6331637 B	18/12/2001
				WO	9813366 A	02/04/1998

WO	03051870	A1	26/06/2003	SE	0104474 D	00/00/0000
				CA	2466491 A	30/05/2003
				SE	0202139 D	00/00/0000

WO	03059893	A1	24/07/2003	DE	10296133 T	15/04/2004
				SE	0200119 D	00/00/0000
				US	20040113409 A	17/06/2004
				EP	1436058 A	14/07/2004
				SE	0201857 D	00/00/0000